



Synthesis of Azasugars as Potent Inhibitors of Glycosidases

Yves Le Merrer,* Lydie Poitout, Jean-Claude Depezay,^a Isabelle Dosbaa, Sabine Geoffroy and Marie-José Foglietti^b


^aUniversité René Descartes, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, associé au CNRS, 45 rue des Saints-Pères, 75006 Paris, France

^bUniversité René Descartes, Laboratoire de Biochimie et de Glycobiologie, 4 avenue de l'Observatoire, 75006 Paris, France

Abstract—A series of enantiomerically pure azasugars (2,5-dideoxy-2,5-imino-D-mannitol, 1-deoxynojirimycin, 1-deoxymannojirimycin, and related compounds) was synthesized from D-mannitol via aminoheterocyclization of C₂-symmetric bis-epoxides and subsequently followed by ring isomerization in few cases. These compounds have been evaluated as inhibitors of several glycosidases (α - and β -D-glucosidases, α -D-mannosidase and α -L-fucosidase). Inhibition studies indicate notably that the polyhydroxylated azepanes are inhibitors of glycosidases, with K_i in the micromolar range. © 1997 Elsevier Science Ltd. All rights reserved.

Introduction

Many polyhydroxylated pyrrolidines or piperidines are compounds that have been shown to selectively inhibit the oligosaccharide processing enzymes (i.e. glycosidases or glycosyltransferases).¹ Azasugars that inhibit these enzymes are potentially useful for treating metabolic disorders such as diabetes,² cancer³ and AIDS.⁴ Among them are (a) polyhydroxylated pyrrolidines such as **1** (DMDP),⁵ **2**,⁶ and **3**,⁷ (b) polyhydroxylated piperidines like 1-deoxynojirimycin **4** (DNJ),⁸ 1-deoxymannojirimycin **5** (DMJ)⁹ and the galactose analogue **6**,¹⁰ (c) the indolizidine alkaloids swainsonine **7**¹¹ and castanospermine **8**,¹² and (d) the pyrrolizidine alkaloid australine **9**¹³ (Scheme 1).



Because of the potential chemotherapeutic applications of such compounds, there is continuing interest in the synthesis of both mono- and bicyclic analogues. In an effort to develop new syntheses of enantiomerically pure azasugars we have examined (Scheme 2) the opening of homochiral C₂-symmetric bis-epoxides by amines. This approach, which involves a regiospecific opening of one epoxy function followed by the expected aminocyclization, would lead to the polyhydroxy-piperidine (6-*exo-tet* process)¹⁴/azepane (7-*endo-tet* process). Isomerization of these structures, after activation of the free hydroxyl groups, via an S_N process either by direct nucleophilic substitution or by neighbouring nitrogen participation would lead to other isomers.



This is in fact a viable approach, since by these two key steps we have obtained DMDP, DNJ, DMDP and various other analogues from D-mannitol, as a single starting material.¹⁵ Our synthetic results have already been disclosed in a preliminary form.¹⁶ We detail here our synthetic routes, the structure of the related compounds and the results of the inhibition analysis.

Results and Discussion


C₂-symmetric bis-epoxides and aminocyclization

Flexible optically pure C₂-symmetric bis-epoxides **12** and **15** were easily obtained, on multigram scales, from the commercially available 1,2:5,6-di-*O*-isopropylidene-D-mannitol **10** (Scheme 3), via the previously described 3,4-di-*O*-benzyl-D-mannitol **11**.¹⁷ Using Mitsunobu conditions,¹⁸ the tetrol **11** was directly transformed in high yield (86%) to the 1,2:5,6-dianhydro-3,4-di-*O*-benzyl-D-mannitol **12** with retention of configuration at C₂ and

Scheme 1.

Aminocyclization**Isomerization**


Scheme 2.



Scheme 3. (a) NaH, BnBr, *n*-Bu₄NI, THF, then AcOH, H₂O, 87%. (b) Ph₃P, DIAD, 130 °C, 86%. (c) TBDMSO, imidazole, DMF, 0 °C, 80%. (d) MsCl, NEt₃, CH₂Cl₂, 98%. (e) HCl, MeOH, then NaOH, H₂O, 75%.

C₅. On the other hand, the tetrol **11** afforded the bis-epoxide **15** with inversion of configuration at C₂ and C₅ in 59% overall yield by the following reactions: selective silylation at the primary 1,6-hydroxyl functions, mesylation at the secondary 2,5-hydroxyl functions, then acidic removal of silyl groups followed by a base promoted intramolecular S_N2 .

The opening of bis-epoxide **12** (Scheme 4) with benzylamine has been examined under different experimental conditions,¹⁶ and among them reaction with excess benzylamine (five equivalents) in refluxing CHCl₃ during 48 h, afforded a mixture of two compounds that could be easily separated by flash chromatography. The piperidine **16a** and the azepane **17a** were isolated in 50 and 45% yield, respectively. Under the same experimental conditions, the diastereomeric bis-epoxide **15** gave the corresponding piperidine **4a** (45%) and azepane **18a** (33%).¹⁹ In contrast, we found that in presence of perchloric acid which should serve as Lewis



Scheme 4. (a) BnNH₂ (5 equivalents), Δ , CHCl₃, 48 h, 50, 45, 45, and 33% yield for **16a**, **17a**, **4a**, and **18a**, respectively. (b) BnNH₂ (10 equivalents), HClO₄ (5 equivalents), H₂O, 28, 67, 9, and 66% yield for **16a**, **17a**, **4a**, and **18a**, respectively. (c) H₂, Pd black, CH₃CO₂H, 100%.

acid to enhance the epoxide opening, fast reaction occurs at 25 °C (4 h), and affords mainly the azepane structure. So, from **12** (or **15**), azepane **17a** (or **18a**) was isolated in 67% (66%) yield, whereas the piperidine **16a** (or **4a**) was isolated in only 28% (9%). The aminocyclization of 1,2:5,6-dianhydro-3,4-*O*-isopropylidene-*D*-mannitol or *L*-iditol gave only the seven-membered azasugars.^{15,20} Comparison of these results indicates that with a flexible bis-epoxide, with acyclic hydroxyl protecting groups at C₃–C₄, the heterocyclization can be directed towards the six- or the seven-membered ring depending on the experimental conditions, whereas, with a more rigid bis-epoxide, for which the protecting group of hydroxyl functions at C₃–C₄ is a *trans*-acetone, heterocyclization furnishes exclusively seven-membered ring.

This aminocyclization can be performed with other primary amines (Table 1), such as 2-phenylethylamine, *N*-acetyl-1,4-butyldiamine, *O*-benzylhydroxylamine, *N,N*-dibenzylhydrazine, or more interestingly with glycine *tert*-butyl ester, tryptamine.²¹ In the particular case of *N*-benzyl piperidines **4a**, **16a** or azepanes **17a**, **18a** hydrogenolytic removal of both *N,O*-benzyl protecting groups using palladium black in acetic acid gave, after purification by ion exchange chromatography, the corresponding azasugars **4** (DNJ), **16**, **17** or **18** in quantitative yield.

With these *N*-benzyl-polyhydroxylated-piperidines **4a** and **16a**, and C₂-symmetric azepanes **17a** and **18a**, in hand, we focused then on their isomerization.

Isomerization of piperidines

Skeletal rearrangement of pyrrolidines, piperidines or azepanes, via an aziridinium or azetidinium salt has

already been reported,²² but this method has found little application in polysubstituted heterocycles. Only few cases have been described in synthesis,²³ and more interestingly in bicyclic alkaloids such as swainsonine or castanospermine.^{23c–e}

The *L-gulo*-piperidine **16a** was readily transformed (Scheme 5) to the dimesylate **21** (100% yield). The latter treated by caesium acetate in dimethylformamide, followed by methanolysis in presence of potassium carbonate gave three compounds **16a**, **17a** and **22a** in 18, 8 and 45% yield, respectively. The first has been identified to the starting *L-gulo*-piperidine, and the second to the *D-manno*-azepane. The third product (**22a**) has been correlated, after hydrogenolytic removal of both *N,O*-protecting groups to the 2,5-dideoxy-2,5-imino-*L*-iditol **22**.²⁴ This diastereomer of DMDP has been obtained in 45% overall yield from **16a** (55% based on recuperation of **16a**). On the other hand, treatment of **16a** with four equivalents of triphenylphosphine-diethyl azodicarboxylate-benzoic acid¹⁸ in THF at 0 °C gave a mixture of only two products (**23b** and **22c**), which after methanolysis and flash chromatography separation, led to **23a** and **22a** in 70 and 18% yield, respectively. Compound **23a** that is the result of an S_N2 reaction at C₂ has been converted by hydrogenolysis to the new compound **23** (5-epi-DNJ).

Thus, from the *L-gulo*-piperidine **16a** these two procedures appear to be different and show that the normal S_N2 reaction competes with the aziridinium pathway. With the mesylate, substitution is more difficult and requires more drastic conditions (heating, long reaction time) that allows the aziridinium formation, followed mainly by ring contraction. In the case of Mitsunobu conditions (fast reaction at 0 °C), the intermolecular S_N2 is easier than the intramolecular participation of the nitrogen, which requires an inversion of the chair conformation (Scheme 6).

Similar reactions were performed (Scheme 7) on the *D-gluco*-piperidine **4a** by treatment with mesyl-chloride (100% yield of dimesylate **24**) and then caesium acetate, or Mitsunobu conditions (four equivalents of Ph₃P-DEAD-PhCO₂H, THF, 0 °C). In all cases, a mixture of two products has been obtained, and its methanolysis (MeOH, K₂CO₃) has furnished, after flash chromatography separation, the initial *D-gluco*-piperidine **4a** (31 and 29% overall yield from **4a**, respectively) and the pyrrolidine **1a** (51 and 64% overall yield from **4a**, respectively). The latter gave **1** (DMDP),²⁵ after hydrogenolysis of both *N,O*-benzyl protecting groups and purification by ion exchange chromatography.

In this case, these two procedures give mainly the ring contraction to the pyrrolidine, due to an easy neighbouring nitrogen participation, since the leaving group is in equatorial position, and subsequent ring opening of the aziridinium at the less substituted side.

To avoid the neighbouring nitrogen participation, we have converted **4a** into the carbamate **4e** (Scheme 8) by

Table 1


RNH ₂	Conditions ^{a,b,c}	Yield ^d	
		piperidine	azepane
PhCH ₂ CH ₂ NH ₂	a	19a : 31%	20a : 66%
AcHN(CH ₂) ₄ NH ₂	b	19b : 48%	20b : 32%
BnONH ₂ ·HCl	c	19c : 22%	20c : 51%
(Bn) ₂ NNH ₂	b	19d : 30%	20d : 23%
^t BuO ₂ CCH ₂ NH ₂ ·HCl	b + Et ₃ N (4 equiv)	19e : 40%	20e : 33%
	a	19f : 26%	20f : 64%
	b	19f : 50%	20f : 45%

^aRNH₂ (10 equiv), HClO₄ (5 equiv), H₂O, 25 °C, 4 h.


^bRNH₂ (5 equiv), CHCl₃, Δ, 48 h.

^cRNH₂ (4 equiv), NEt₃ (5 equiv), H₂O, 80 °C, 15 h.


^dUnoptimized yield for each isolated compound.




Scheme 5. (a) MsCl (2.3 equivalents), Et₃N, CH₂Cl₂, 100%. (b) AcOCs, DMF. (c) MeOH, K₂CO₃. (d) H₂, Pd black, CH₃CO₂H, 100%. (e) Ph₃P-DEAD-PhCO₂H (4 equiv), THF.



Scheme 6.



Scheme 7. For reaction conditions of a, b, c, d and e see Scheme 5.



Scheme 8. (a) H₂, Pd(OH)₂/C, EtOH. (b) BnOCOCl, K₂CO₃, DMF. (c) Ph₃P-DEAD-PhCO₂H (4 equivalents), THF. (d) MeOH, K₂CO₃ in vacuo. (e) H₂, Pd black, AcOH. (f) MeOH, K₂CO₃. (g) Ph₃P-DEAD-HN₃ (3 equivalents), THF. (h) Na₂Cr₂O₇, H₂SO₄, Et₂O, H₂O. (i) CH₂N₂.


selective hydrogenolysis of the benzyl–nitrogen bond using Pearlman's catalyst,²⁶ followed by action of benzylchloroformate (90% overall yield). The carbamate **4e** underwent substitution under Mitsunobu conditions in presence of benzoic acid to yield only **25** (91%). To confirm the inversion of configuration at C₂, **25** was fully deprotected by methanolysis in very mild conditions (MeOH, K₂CO₃, in vacuo, 40 °C) and hydrogenolysis to give **5** (DMJ).²⁷

Furthermore, methanolysis of the carbamate **4e** led to the oxazolidinone **26** (96%), and the Mitsunobu reaction in presence of hydrazoic acid²⁸ in benzene yielded the azido-oxazolidinone **27** (90%). Inversion of configuration at C₂ was confirmed by the modification of the coupling constants in ¹H NMR: ³J_{3,4} = ³J_{4,5} = ³J_{2,3} = 9 Hz to ³J_{3,4} = ³J_{4,5} = 9 Hz and ³J_{2,3} = 2.5 Hz for **26** and **27**, respectively. The oxazolidinone **27** was subjected to methanolysis, and then hydrogenolysis to give the 2-amino-2-deoxy-DMJ **29**.²⁹

Interestingly, selective oxidation of the primary hydroxyl group of the *N*-Cbz protected piperidine **4e** can be efficiently performed by Na₂Cr₂O₇ under biphasic conditions³⁰ to give **30a**, which was fully characterized as its methyl ester **30b**. The moderate yield (50%) for **30a** was due to the difficulty in product extraction. Subsequent hydrogenolysis of **30a** afforded the (2*S*,3*R*,4*R*,5*S*)-3,4,5-trihydroxypipercolic acid **30** in quantitative yield.³¹ By comparison, oxidation of the *N*-Cbz analogue derived from the *L*-gulo-piperidine **16a** gave the corresponding acid in poor yield (15%), and a hemiketal (10%) which results of both oxidation at the primary and the secondary alcohol functions.

Isomerization of azepanes (Scheme 9)

Reaction of the azepane **17a** with 1.2 equivalents of triphenylphosphine-diethyl azodicarboxylate-benzoic acid at 0 °C yielded a mixture of two monobenzoyl



Scheme 9. (a) $\text{Ph}_3\text{P-DEAD-PhCO}_2\text{H}$ (1.2 equiv), THF. (b) MeOH, K_2CO_3 . (c) $\text{Ph}_3\text{P-DEAD}$ (1.2 equiv), THF. (d) H_2 , Pd black, AcOH. (e) H_2 , $\text{Pd}(\text{OH})_2/\text{C}$, EtOH.

Table 2

Enzyme	Inhibitor ^{a,b}										
	1	4	5	16	17	18	22	23	29	30	31
α -Glucosidase	97% 0.03 (c)	100% 0.44 (c)	100% 18 (c)	30% —	55% 70 (c)	97% 4.8 (c)	55% —	74% 65 (c)	88% 53 (c)	66% 83 (c)	6% —
β -Glucosidase	91% 160 (c)	64% 1700	39% 1400 (c)	13% —	1% —	86% 17 (c)	42% —	11% —	4% —	8% —	0% —
α -Mannosidase	38% —	44% 1000	49% 600 (c)	15% —	1% —	25% —	40% —	17% —	98% 20 (c)	31% —	3% —
α -Fucosidase	35% —	27% 500	100% 0.13 (c)	94% 22 (c)	94% 28 (c)	4% —	84% 170 (c)	50% 260 (c)	63% 190 (c)	2% —	29% —

^a% Inhibition determined at 1 mM concentration of inhibitor.

^bInhibition constants (K_i (μM)) in bold, and mode of inhibition (c for competitive) in parentheses were determined by the Lineweaver–Burk plot.

derivatives **17b** and **16c** (65%). By methanolysis, **17b** gave back alcohol **17a** (36%), and **16c** afforded the piperidine **16a** (24%). This result shows that the reaction undergoes via an aziridinium intermediate, the nucleophilic opening of which giving rise to the formation of the two regioisomers **17b** and **16c**.³²

Similar treatment of the *L*-ido-azepane **18a** gave only one product **31a** (80%). In absence of benzoic acid, the yield of **31a** could be improved up to 94%. The chiral bridged morpholine **31** was then obtained after full deprotection by hydrogenolysis.³³ The formation of the bridged compound **31** can be interpreted as an intramolecular displacement of the alkoxyphosphonium intermediate by the other free hydroxyl group of the azepane, concurrently to the evolution towards the aziridinium. This bridged morpholine **31** is an interesting structure because the *N*-substituted derivatives possess various biological activities.³⁴

Inhibition studies³⁵

The obtained azasugars (Table 2) were evaluated as inhibitors of different glycosidases (α -D-glucosidase, β -D-glucosidase, α -D-mannosidase and α -L-fucosidase).

Results obtained for DMDP **1**, DNJ **4**, and DMJ **5** are comparable with those reported. For the other compounds, never described or for which glycosidase inhibitor properties have never been reported, interesting results have been obtained. For example, **16**, a diastereomer of DNJ, is a competitive inhibitor of α -L-fucosidase ($K_i = 22 \mu\text{M}$), while **23** (5-epi-DNJ) inhibits α -D-glucosidase ($K_i = 65 \mu\text{M}$). Furthermore, the C_2 -amino derivative of DMJ **29** shows analogous properties to this latter, but with weaker inhibition for α -L-fucosidase ($K_i = 190 \mu\text{M}$ against 0.13 for DMJ). The glucuronic acid **30**, known as α -D-glucuronidase and iduronidase inhibitors,³⁶ is also an α -D-glucosidase inhibitor ($K_i = 83 \mu\text{M}$). Finally, the polyhydroxylated azepanes **17** and **18** are inhibitors of glycosidases. In particular **18** inhibits α -D-glucosidase ($K_i = 4.8 \mu\text{M}$) and β -D-glucosidase ($K_i = 17 \mu\text{M}$), while its diastereomer **17** inhibits α -D-glucosidase ($K_i = 70 \mu\text{M}$) and α -L-fucosidase ($K_i = 28 \mu\text{M}$).³⁷ These K_i values, in the low micromolar range, show that the greater flexibility of the seven-membered ring makes these compounds capable of mimicking the putative oxonium ion transition state that it generated during the carbohydrate hydrolysis by glycosidases. By comparison, the rigid bridged morpholine **31** abolishes the inhibition.

Conclusion

The present work outlined an efficient synthetic pathway to construct various azasugars with a pyrrolidine, piperidine, or an azepane framework. Biological studies indicate, notably, that the polyhydroxylated azepanes are inhibitors of glycosidases with the K_i values in the low micromolar range. Further utilization of this methodology in the synthesis of other azasugars and related systems will be reported in due course.

Experimental

Prior to use, THF and Et₂O were distilled from sodium benzophenone and CH₂Cl₂ from P₂O₅. CH₂Cl₂ and AcOEt were filtered on K₂CO₃ prior to use. ¹H and ¹³C NMR (250 and 63 MHz, respectively) were recorded in CDCl₃ (unless indicated) on a Bruker instrument. Chemical shifts are reported in δ (ppm) and coupling constants are given in Hz. Mass spectra, chemical ionization (CI), and high resolution (HRMS), were recorded in Service de Spectrométrie de Masse, Université Pierre et Marie Curie. Specific rotations were measured on a Perkin Elmer 241C polarimeter with sodium (589 nm) lamp. All reactions were run under an argon atmosphere, unless otherwise stated, and were monitored by thin-layer chromatography with Merck 60F-254 precoated silica (0.2 μ m) on glass. Chromatography was performed with Merck Kieselgel 60 (200–500 μ m) or 60 H (5–40 μ m). Spectroscopic (¹H and ¹³C NMR, MS)/analytical data were obtained using chromatographically homogeneous samples.

Synthesis of bis-epoxides 12 and 15

1,2:5,6-Dianhydro-3,4-di-*O*-benzyl-D-mannitol (12). A suspension of the tetrol **11**¹⁷ (12 g, 33 mmol) in toluene (150 mL) was concentrated twice in vacuo to avoid any trace of water. Then toluene (150 mL) and triphenylphosphine (20.2 g, 77 mmol) were added, and the resulting mixture was concentrated again in vacuo until it remained a volume of ca. 60 mL. The mixture was then cooled to 0 °C, and diisopropyl diazodicarboxylate (DIAD) (15.4 mL, 78 mmol) was slowly added. After 30 min stirring at 0 °C, the pale-orange resulting mixture was concentrated in vacuo and heated for 2.5 h under $P = 0.01$ mmHg to 130 °C. Flash chromatography of the crude (cyclohexane:AcOEt, 8:2) afforded 9.2 g (86%) of **12** (R_f 0.35). [α]_D+5 (c 1.0, CH₂Cl₂); ¹H NMR 7.26 (s, 10 H, Ph), 4.66, 4.55 (AB, 4 H, OCH₂Ph), 3.38 (m, 2 H, H₃), 3.11 (m, 2 H, H₂), 2.73 (dd, 2 H, H₁), 2.61 (dd, 2 H, H_{1'}), ² $J_{AB} = 12$, ² $J_{1,1'} = 5.5$, ³ $J_{1,2} = 4$, ³ $J_{1',2} = 2.5$; ¹³C NMR 138.0, 130.8, 128.7, 127.9, 127.8 (Ph), 78.5 (C₃), 73.5 (OCH₂Ph), 50.6 (C₂), 46.0 (C₁); Anal. calcd for C₂₀H₂₂O₄: C, 73.60, H, 6.79; found: C, 73.50, H, 6.94.

3,4-Di-*O*-benzyl-1,6-di-*O*-*tert*-butyl dimethylsilyl-D-mannitol (13). To a stirred solution of **11**¹⁷ (12 g, 33 mmol) in DMF (32 mL) was successively added at 0 °C imidazole (9 g, 132 mmol), and *tert*-butyldimethylsilyl

chloride (10.2 g, 69.3 mmol). After 2 h stirring at 0 °C, aq saturated solution of NH₄Cl (60 mL) was added, and the mixture was extracted with CH₂Cl₂ (3 \times 60 mL). The combined organic layers were washed with brine, dried (MgSO₄), and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 85:15) afforded 15.6 g (80%) of **13** (R_f 0.30). [α]_D +30 (c 1.0, CH₂Cl₂); ¹H NMR 7.35 (m, 10 H, Ph), 4.72, 4.60 (AB, 4 H, OCH₂Ph), 3.90–3.80 (m, 4 H, H_{2,3}), 3.76 (dd, 2 H, H₁), 3.62 (dd, 2 H, H_{1'}), 0.90 (s, 18 H, *t*-BuSi), 0.07 (s, 12 H, Me₂Si), ² $J_{AB} = 12$, ² $J_{1,1'} = 10$, ³ $J_{1,2} = 3$, ³ $J_{1',2} = 5$; Anal. calcd for C₃₂H₅₄O₆Si₂: C, 65.09, H, 9.22; found: C, 65.06, H, 9.36.

3,4-Di-*O*-benzyl-1,6-di-*O*-*tert*-butyl dimethyl silyl-2,5-di-*O*-mesyl-D-mannitol (14). To a cooled solution of **13** (14.45 g, 24.4 mmol) in CH₂Cl₂ (30 mL) at 0 °C was successively added NEt₃ (13.8 mL, 100 mmol), and methanesulfonyl chloride (5.7 mL, 73.5 mmol). After 15 min stirring at 0 °C, the reaction was quenched by addition of water (30 mL) and diluted with CH₂Cl₂ (40 mL). After decantation and extraction with CH₂Cl₂ (3 \times 60 mL), the combined organic layers were washed with brine, dried (MgSO₄), and concentrated in vacuo. The crude **14** was used in the next step without further purification. [α]_D +20 (c 1.3, CH₂Cl₂); ¹H NMR 7.30 (m, 10 H, Ph), 4.80 (m, 2 H, H₂), 4.76, 4.66 (AB, 4 H, OCH₂Ph), 4.12 (dd, 2 H, H₁), 3.99 (s, 2 H, H₃), 3.24 (dd, 2 H, H_{1'}), 0.90 (s, 18 H, *t*-BuSi), 0.07 (s, 12 H, Me₂Si), ² $J_{AB} = 12$, ² $J_{1,1'} = 12$, ³ $J_{1,2} = 3.5$, ³ $J_{1',2} = 5.5$.

1,2:5,6-Dianhydro-3,4-di-*O*-benzyl-L-iditol (15). To a cooled solution of **14** (18.2 g, 24.2 mmol) in MeOH (41 mL) at 0 °C was slowly added concentrated aqueous hydrochloric acid (5.2 mL, 58.8 mmol). After 2 h stirring at 20 °C, the mixture was cooled to 0 °C and an aq solution of KOH (20%, 42 mL, 147 mmol) was added. The resulting mixture was stirred for 3 h at 20 °C, then concentrated in vacuo. After addition of water (25 mL) and CH₂Cl₂ (50 mL), decantation, extraction with CH₂Cl₂ (3 \times 60 mL), the combined organic layers were washed with a saturated aqueous solution of NH₄Cl, dried (MgSO₄), and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 7:3) afforded 6.19 g (78%) of **15** (R_f 0.30). Mp 28 °C; [α]_D –43 (c 1.1, CH₂Cl₂); ¹H NMR 7.35 (s, 10 H, Ph), 4.85, 4.61 (AB, 4 H, OCH₂Ph), 3.29 (m, 2 H, H₃), 3.21 (m, 2 H, H₂), 2.74 (dd, 2 H, H₁), 2.53 (dd, 2 H, H_{1'}), ² $J_{AB} = 12$, ² $J_{1,1'} = 5$, ³ $J_{1,2} = 4.5$, ³ $J_{1',2} = 2.5$; ¹³C NMR 137.9, 128.3, 127.9, 127.7 (Ph), 80.7 (C₃), 72.3 (OCH₂Ph), 52.4 (C₂), 43.1 (C₁); Anal. calcd for C₂₀H₂₂O₄: C, 73.60, H, 6.79; found: C, 73.46, H, 6.91.

Aminocyclization of bis-epoxide 12 or 15 with benzylamine

In aprotic solvent, method (a) in Scheme 4: a mixture of **12** (3.5 g, 10.74 mmol) and benzylamine (5.9 mL, 53.7 mmol) in CHCl₃ (50 mL) was refluxed for 48 h. Concentration in vacuo and flash chromatography (CH₂Cl₂:acetone, 9:1) afforded 2.3 g (50%) of **16a** (R_f

0.35) and 2.1 g (45%) of **17a** (R_f 0.30). From **15** (2.0 g, 6.13 mmol), 1.2 g (45%) of **4a** (R_f 0.30) and 0.88 g (33%) of **18a** (R_f 0.35) have been obtained.

In protic solvent, method (b) in Scheme 4: to **12** (2 g, 6.13 mmol) in water (40 mL) was added benzylamine (6.7 mL, 61.3 mmol) followed by HClO_4 in aqueous solution 70% (2.6 mL, 30.6 mmol). After 4 h stirring at 20 °C, CH_2Cl_2 (30 mL) was added. After decantation and extraction (4 \times 50 mL), the combined organic layers were washed with brine, dried (Na_2SO_4), and concentrated in vacuo. Flash chromatography of the crude (CH_2Cl_2 :acetone, 9:1) afforded 0.74 g (28%) of **16a** (R_f 0.35) and 1.78 g (67%) of **17a** (R_f 0.30). From **15** (1.5 g, 4.6 mmol), 0.18 g (9%) of **4a** (R_f 0.30) and 1.31 g (66%) of **18a** (R_f 0.35) have been obtained.

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-D-glucitol (4a). Mp 109 °C; $[\alpha]_D +4$ (c 1.1, CHCl_3); ^1H NMR 7.30 (m, 15 H, Ph), 4.90 (dd, 2 H, OCH_2Ph), 4.71 (m, 2 H, OCH_2Ph), 4.50, 3.86 (AB, 2 H, NCH_2Ph), 4.01 (dd, 1 H, H_6), 3.69 (t, 1 H, H_4), 3.61 (ddd, 1 H, H_2), 3.39 (t, 1 H, H_3), 3.36 (d, 1 H, $\text{H}_{6'}$), 3.05 (dd, 1 H, H_{1a}), 2.44 (m, 1 H, H_5), 2.15 (dd, 1 H, H_{1c}), $^3J_{3,4} = ^3J_{4,5} = ^3J_{2,3} = 8.5$, $^3J_{2,1e} = 4$, $^3J_{2,1a} = 9.5$, $^3J_{6,5} = 3$, $^2J_{1,1'} = 11$, $^2J_{6,6'} = 12$, $^2J_{A,B} = 13$; ^{13}C NMR 138.6, 138.3, 138.0, 128.8, 128.5, 128.4, 127.8, 127.4 (Ph), 85.8, 78.3 ($\text{C}_{3,4}$), 74.8, 74.6 (OCH_2Ph), 69.3 (C_2), 65.6 (C_5), 58.2 (C_6), 57.3 (NCH_2Ph), 55.2 (C_1); Anal. calcd for $\text{C}_{27}\text{H}_{31}\text{NO}_4$, 0.4 H_2O : C, 73.64, H, 7.22, N, 3.18; found: C, 73.68, H, 7.14, N, 3.24.

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-L-gulitol (16a). Mp 75 °C; $[\alpha]_D -9$ (c 1.0, CHCl_3); ^1H NMR 7.30 (m, 15 H, Ph), 4.70–4.57 (m, 4 H, OCH_2Ph), 4.06 (dd, 1 H, H_4), 4.02 (m, 1 H, H_2), 3.92 (d, 2 H, NCH_2Ph), 3.84 (dd, 1 H, H_6), 3.69 (m, 2 H, $\text{H}_{3,6'}$), 3.11 (m, 1 H, H_5), 2.76 (m, 2 H, $\text{H}_{1,1'}$), $^3J_{4,5} = 5$, $^3J_{3,4} = 8$, $^3J_{5,6} = 6$, $^3J_{5,6'} = 7$, $^2J_{6,6'} = 11$, $^3J_{2,3} = 3$, $^2J_{\text{NCH}_2\text{Ph}} = 2$; ^{13}C NMR 138.9, 138.1, 137.9, 128.9, 128.5, 127.9, 127.7, 127.2 (Ph), 78.1, 75.4 ($\text{C}_{3,4}$), 73.3, 72.5 (OCH_2Ph), 67.9 (C_2), 59.8 (C_5), 59.3 (C_6), 57.9 (NCH_2Ph), 49.3 (C_1); MS (CI, NH_3) 434 ($\text{M}^+ + 1$).

N-Benzyl-3,4-di-O-benzyl-1,6-dideoxy-1,6-imino-D-mannitol (17a). $[\alpha]_D -6$ (c 1.0, CHCl_3); ^1H NMR 7.30 (m, 15 H, Ph), 4.75, 4.60 (AB, 4 H, OCH_2Ph), 4.08 (m, 2 H, H_2), 3.84 (s, 2H, H_3), 3.68 (s, 2 H, NCH_2Ph), 2.83 (dd, 2 H, H_1), 2.71 (dd, 2 H, $\text{H}_{1'}$), $^2J_{A,B} = 12$, $^3J_{1,2} = 4$, $^3J_{1',2} = 6.5$, $^2J_{1,1'} = 13$; ^{13}C NMR 138.3, 128.7, 128.3, 127.8, 127.6, 127.2 (Ph), 80.9 (C_3), 73.1 (OCH_2Ph), 68.6 (C_2), 63.4 (NCH_2Ph), 57.0 (C_1); Anal. calcd for $\text{C}_{27}\text{H}_{31}\text{NO}_4$, 0.5 H_2O : C, 73.30, H, 7.24, N, 3.16; found: C, 73.45, H, 7.26, N, 3.16.

N-Benzyl-3,4-di-O-benzyl-1,6-dideoxy-1,6-imino-L-iditol (18a). Mp 77 °C; $[\alpha]_D +15$ (c 1.6, CHCl_3); ^1H NMR 7.30 (m, 15 H, Ph), 4.76, 4.62 (AB, 4 H, OCH_2Ph), 3.81 (m, 2 H, H_2), 3.71 (d, 2 H, NCH_2Ph), 3.63 (dd, 2 H, H_3), 2.92 (d, 2H, H_1), 2.63 (dd, 2H, $\text{H}_{1'}$), $^2J_{A,B} = 11.5$, $^3J_{1,1'} = 12.5$, $^3J_{1',2} = 8$, $^3J_{2,3} = 4$, $^3J_{3,4} = 1.5$; ^{13}C NMR 138.1, 137.8, 129.1, 128.5, 127.8, 127.6 (Ph), 86.7 (C_3),

73.7 (OCH_2Ph), 68.3 (C_2), 63.6 (NCH_2Ph), 57.6 (C_1); HMRS calcd for $\text{C}_{20}\text{H}_{24}\text{NO}_4$ ($\text{M}^+ - \text{PhCH}_2$) 342.1705; found 342.1706.

Aminocyclization of **12** with other amines

Aminocyclization of **12** (2 g, 6.13 mmol) with 2-phenylethylamine (7.7 mL, 6.13 mmol) was carried out under identical conditions described above in protic solvent, to give after flash chromatography (CH_2Cl_2 :acetone, 85:15) 850 mg (31%) of **19a** (R_f 0.35) and 1.81 g (66%) of **20a** (R_f 0.24).

3,4-Di-O-benzyl-1,5-dideoxy-1,5-imino-N-(2'-phenylethyl)-L-gulitol (19a): $[\alpha]_D +1$ (c 1.0, CHCl_3); ^1H NMR 7.40–7.10 (m, 15 H, Ph), 4.75–4.52 (m, 4 H, OCH_2Ph), 4.02 (m, 1 H, H_2), 3.95 (dd, 1 H, H_4), 3.80 (dd, 1 H, H_6), 3.64 (dd, 1 H, H_3), 3.59 (dd, 1 H, $\text{H}_{6'}$), 3.20–2.68 (m, 7 H, $\text{H}_{5,1,1'}$, $(\text{CH}_2)_2$), $^3J_{3,4} = 8$, $^3J_{4,5} = 5$, $^3J_{2,3} = 3.5$, $^3J_{6,5} = 6$, $^3J_{6',5} = 6.5$, $^2J_{6,6'} = 11.5$; ^{13}C NMR 140.0, 137.9, 128.6, 128.4, 128.3, 128.0, 127.9, 127.6, 126.0 (Ph), 77.9, 75.7 ($\text{C}_{3,4}$), 73.2, 72.4 (OCH_2Ph), 67.7 (C_2), 59.9 (C_5), 58.0 (C_6), 56.4 (CH_2), 50.1 (C_1), 33.9 (CH_2); MS (CI, NH_3) 448 ($\text{M}^+ + 1$).

3,4-Di-O-benzyl-1,6-dideoxy-1,6-imino-N-(2'-phenylethyl)-D-mannitol (20a). $[\alpha]_D +5$ (c 1.0, CHCl_3); ^1H NMR 7.40–7.13 (m, 15 H, Ph), 4.76–4.52 (AB, 4 H, OCH_2Ph), 4.07 (m, 2 H, H_2), 3.77 (s, 2H, H_3), 2.91 (dd, 2 H, H_1), 2.85–2.70 (m, 6 H, $\text{H}_{1'}$, $(\text{CH}_2)_2$), $^2J_{A,B} = 12$, $^3J_{1,2} = 4$, $^2J_{1,1'} = 13$.

Aminocyclization of **12** (90 mg, 0.276 mmol) with *N*-acetyl-1,4-butyl-diamine (143 mg, 1.1 mmol) was carried out under identical conditions described above in aprotic solvent (refluxing for 6 h), to give after flash chromatography (CH_2Cl_2 :MeOH, 9:1) 60 mg (48%) of **19b** (R_f 0.35) and 40 mg (32%) of **20b** (R_f 0.25).

3,4-Di-O-benzyl-1,5-dideoxy-1,5-N-(1-N'-acetyl-1-aminobut-4-yl)-imino-L-gulitol (19b). $[\alpha]_D +5$ (c 0.9, CHCl_3); ^1H NMR 7.30 (m, 10 H, Ph), 6.0 (m, 1 H, NH), 4.75–4.53 (m, 4 H, OCH_2Ph), 4.0 (m, 1 H, H_2), 3.92 (dd, 1 H, H_4), 3.81 (dd, 1 H, H_6), 3.68–3.57 (m, 2 H, $\text{H}_{3,6'}$), 3.30–2.90 (m, 2 H, CH_2NH), 3.0 (m, 1 H, H_5), 2.83–2.57 (m, 4 H, $\text{H}_{1,1'}$, CH_2N), 1.92 (s, 3 H, CH_3), 1.45 (m, 4 H, $(\text{CH}_2)_2$), $^3J_{3,4} = 7.5$, $^3J_{4,5} = 4.5$, $^3J_{6,5} = 6$, $^2J_{6,6'} = 11.5$; ^{13}C NMR 170.2 (CO), 138.0, 137.8, 128.5, 128.0, 127.7 (Ph), 77.5, 76.2 ($\text{C}_{3,4}$), 73.4, 72.6 (OCH_2Ph), 67.2 (C_2), 60.4 (C_5), 58.1 (C_6), 54.1, 50.3, 39.1, 27.1, 24.4 (C_1 , CH_2), 23.2 (CH_3); HMRS calcd for $\text{C}_{25}\text{H}_{33}\text{N}_2\text{O}_4$ ($\text{M}^+ - \text{CH}_2\text{OH}$) 425.2440, found 425.2438.

3,4-Di-O-benzyl-1,6-dideoxy-N-(1-N'-acetyl-1-aminobut-4-yl)-imino-D-mannitol (20b). $[\alpha]_D +2.5$ (c 1.5, CHCl_3); ^1H NMR 7.30 (m, 10 H, Ph), 6.10 (m, 1 H, NH), 4.72–4.61 (AB, 4 H, OCH_2Ph), 4.10 (m, 2 H, H_2), 3.78 (s, 2 H, H_3), 3.30–3.05 (m, 2 H, CH_2NH), 2.80 (m, 4 H, $\text{H}_{1,1'}$), 2.58 (m, 2 H, CH_2N), 1.92 (s, 3 H, CH_3), 1.50 (m, 4 H, $(\text{CH}_2)_2$), $^2J_{A,B} = 12$; ^{13}C NMR 170.4 (CO), 138.2,

128.4, 127.9, 127.8 (Ph), 80.4 (C₃), 73.4 (OCH₂Ph), 68.2 (C₂), 58.4, 56.6, 39.1, 26.9, 24.0 (C₁, (CH₂)₄), 23.2 (CH₃); MS (CI, NH₃) 457 (M⁺+1).

Aminocyclization of **12** (100 mg, 0.306 mmol) in water (3 mL) with *O*-benzyl-hydroxylamine hydrochloride (196 mg, 1.22 mmol) was carried out at 80 °C for 15 h in presence of NEt₃ (212 μL, 1.53 mmol), to give after flash chromatography (CH₂Cl₂:Et₂O, 92:8) 26 mg (22%) of **19c** (*R*_f 0.28) and 61 mg (51%) of **20c** (*R*_f 0.19).

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-L-gulitol (19c). [α]_D +58 (c 0.7, CHCl₃); ¹H NMR 7.30 (m, 15 H, Ph), 4.77 (AB, 2 H, NOCH₂Ph), 4.64–4.40 (m, 4 H, OCH₂Ph), 4.07 (m, 1 H, H₂), 3.92 (m, 1 H, H₆), 3.80 (m, 1 H, H₄), 3.72 (dd, 1 H, H_{6'}), 3.63 (m, 1 H, H₃), 3.43 (dd, 1 H, H₁), 2.95 (m, 1 H, H₅), 2.79 (t, 1 H, H_{1'}), ²J_{A,B} = 2, ³J_{1,2} = 4.2, ²J_{1,1'} = ³J_{1',2} = 10, ²J_{6,6'} = 10.5, ³J_{6',5} = 8; ¹³C NMR 137.5, 137.1, 136.5, 128.9, 128.6, 128.4, 128.1, 127.7 (Ph), 76.5 (NOCH₂Ph), 75.3, 74.9 (C_{3,4}), 73.0, 72.7 (OCH₂Ph), 66.0 (C₂), 64.8 (C₅), 62.5 (C₆), 56.1 (C₁); HMRS calcd for C₂₆H₂₈NO₄ (M⁺ – CH₂OH) 418.2018; found 418.2015.

N-Benzyl-3,4-di-O-benzyl-1,6-dideoxy-1,6-imino-D-mannitol (20c). Mp 45 °C; [α]_D – 4 (c 0.9, CHCl₃); ¹H NMR 7.30 (m, 15 H, Ph), 4.73–4.59 (AB, 4 H, OCH₂Ph), 4.65 (s, 2 H, NOCH₂Ph), 4.11 (m, 2 H, H₂), 3.77 (s, 2 H, H₃), 3.18 (m, 4 H, H_{1,1'}), ²J_{A,B} = 11; ¹³C NMR 138.1, 137.2, 128.8, 128.4, 128.3, 127.8 (Ph), 79.9 (C₃), 74.3 (NOCH₂Ph), 73.5 (OCH₂Ph), 67.3 (C₂), 60.9 (C₁); HMRS calcd for C₂₆H₂₈NO₄ (M⁺ – C₇H₇) 358.1654; found 358.1655.

Aminocyclization of **12** (100 mg, 0.306 mmol) with *N,N*-dibenzylhydrazine (259 mg, 1.224 mmol) in CHCl₃ (2 mL) was carried out at reflux for 10 days, to give after flash chromatography (CH₂Cl₂:Et₂O, 92:8, then 97:3) 49 mg (30%) of **19d** (*R*_f 0.35) and 38 mg (23%) of **20d** (*R*_f 0.28).

3,4-Di-O-benzyl-1,5-dideoxy-1,5-*N,N*-dibenzylhydrazino-L-gulitol (19d). [α]_D +40 (c 1.1, CHCl₃); ¹H NMR 7.40–7.05 (m, 20 H, Ph), 4.70–4.18 (m, 4 H, OCH₂Ph), 4.03 (m, 1 H, H₂), 3.85 (m, 2 H, NCH₂Ph), 3.65 (m, 1 H, H₃), 3.54 (d, 2 H, NCH₂Ph), 3.45 (m, 1 H, H₄), 3.23–3.19 (m, 3 H, H_{6,6',1}), 3.08 (m, 1 H, H₅), 2.76 (t, 1 H, H_{1'}), ²J_{NCH₂Ph} = 12, ²J_{1,1'} = ³J_{1',2} = 10; ¹³C NMR 137.9, 137.8, 137.6, 129.9, 128.6, 128.2, 127.9, 127.5, 127.3, 127.1 (Ph), 76.3, 75.6 (C_{3,4}), 72.7 (OCH₂Ph), 66.7 (C₂), 65.0 (C₆), 58.5 (C₅), 53.9 (NCH₂Ph), 45.1 (C₁); HMRS calcd for C₂₇H₃₁N₂O₄ (M⁺ – C₇H₇) 447.2884; found 447.2884.

3,4-Di-O-benzyl-1,6-dideoxy-1,6-*N,N*-dibenzylhydrazino-D-mannitol (20d). [α]_D +6 (c 0.7, CHCl₃); ¹H NMR 7.40–7.20 (m, 20 H, Ph), 4.64–4.50 (AB, 4 H, OCH₂Ph), 3.95 (m, 2 H, H₂), 3.64 (s, 4 H, NCH₂Ph), 3.50 (s, 2 H, H₃), 3.10 (dd, 2 H, H₁), 2.99 (dd, 1 H, H_{1'}), ²J_{A,B} = 11, ³J_{1,2} = 4, ³J_{1',2} = 6, ²J_{1,1'} = 13; ¹³C NMR 138.8, 138.4, 128.6, 128.3, 127.9, 127.6, 127.2 (Ph), 80.5 (C₃), 73.3

(OCH₂Ph), 68.4 (C₂), 54.9, 54.3 (NCH₂Ph, C₁); HMRS calcd for C₂₇H₃₁N₂O₄ (M⁺ – C₇H₇) 447.2884; found 447.2880.

Aminocyclization of **12** (100 mg, 0.306 mmol) with glycine *tert*-butyl ester hydrochloride (103 mg, 0.612 mmol) was carried out under identical conditions described above, in aprotic solvent (refluxing for 48 h) in presence of Et₃N (171 μL, 1.22 mmol), to give after flash chromatography (AcOEt:cyclohexane:CH₂Cl₂, 5:3:2.5) 56 mg (40%) of **19e** (*R*_f 0.31) and 46 mg (33%) of **20e** (*R*_f 0.35).

3,4-Di-O-benzyl-1,5-dideoxy-1,5-[*tert*-butyloxycarbonylmethyl]-imino-L-gulitol (19e). [α]_D – 2 (c 1.1, CHCl₃); ¹H NMR 7.30 (m, 10 H, Ph), 4.70–4.50 (m, 4 H, OCH₂Ph), 3.99 (m, 1 H, H₂), 3.87 (dd, 1 H, H₄), 3.78–3.58 (m, 4 H, H_{6,6',3}, CH₂CO₂), 3.40 (d, 1 H, CH₂CO₂), 3.20 (m, 1 H, H₅), 2.91 (d, 2 H, H_{1',1}), 1.43 (s, 9 H, Me₃), ³J_{4,5} = 4.5, ³J_{3,4} = 7, ³J_{1,2} = ³J_{1',2} = 4; ¹³C NMR 171.5 (CO), 138.0, 137.8, 128.5, 128.0, 127.9, 127.8 (Ph), 81.3 (CMe₃), 77.3, 75.6 (C_{3,4}), 73.0, 72.6 (OCH₂Ph), 67.4 (C₂), 59.9 (C₅), 59.1 (C₆), 57.0 (C₁), 51.3 (CH₂CO₂), 28.1 (Me₃); HMRS calcd for C₂₁H₂₆NO₄ (M⁺ – CO₂*t*-Bu) 356.1861; found 356.1861.

3,4-Di-O-benzyl-1,6-dideoxy-1,6-[*tert*-butyloxycarbonylmethyl]-imino-D-mannitol (20e). [α]_D – 1 (c 1.2, CHCl₃); ¹H NMR 7.30 (m, 10 H, Ph), 4.77–4.62 (m, 4 H, OCH₂Ph), 4.07 (m, 2 H, H₃), 3.82 (s, 2 H, H₂), 3.29 (s, 2 H, CH₂CO₂), 3.01 (dd, 2 H, H₁), 2.81 (dd, 2 H, H_{1'}), 1.43 (s, 9 H, Me₃), ²J_{A,B} = 12, ³J_{1,2} = 3, ³J_{1',2} = 6, ²J_{1,1'} = 13; ¹³C NMR 170.7 (CO), 138.5, 128.3, 127.9, 127.6 (Ph), 81.5 (CMe₃), 80.6 (C₃), 73.5 (OCH₂Ph), 69.0 (C₂), 60.9 (CH₂CO₂), 57.1 (C₁), 28.1 (Me₃); HMRS calcd for C₂₁H₂₆NO₄ (M⁺ – CO₂*t*-Bu) 356.1861; found 356.1865.

Aminocyclization of **12** (2.4 g, 7.36 mmol) with tryptamine (4.71 g, 29.44 mmol) was carried out under identical conditions described above, in aprotic solvent (refluxing for 24 h), to give after flash chromatography (CH₂Cl₂:acetone, 7:3) 1.79 g (50%) of **19f** (*R*_f 0.35) and 1.81 g (45%) of **20f** (*R*_f 0.30).

3,4-Di-O-benzyl-1,5-dideoxy-1,5-[2'-(1H-indol-3-yl)-ethyl]-imino-L-gulitol (19f). [α]_D – 9 (c 1.0, CHCl₃); ¹H NMR 7.94 (s, 1 H, NH), 7.57 (d, 1 H indol), 7.2–6.96 (m, 14 H, Ar), 4.71–4.52 (m, 4 H, OCH₂Ph), 4.02 (m, 1 H, H₂), 3.96 (dd, 1 H, H₄), 3.80 (dd, 1 H, H₆), 3.64 (dd, 1 H, H₃), 3.60 (dd, 1 H, H_{6'}), 3.23–2.80 (m, 7 H, H_{1',1,5}, (CH₂)₂), ³J_{2,3} = 3.5, ³J_{3,4} = 8, ³J_{4,5} = 5, ³J_{5,6} = 6, ³J_{5,6'} = 7, ²J_{6,6'} = 11; ¹³C NMR 138.0, 137.9, 136.2, 128.4, 128.0, 127.9, 127.7, 127.3, 121.7, 119.1, 118.7, 113.7, 111.1 (Ar), 77.8, 75.7 (C_{3,4}), 73.2, 72.4 (OCH₂Ph), 67.6 (C₂), 59.9 (C₅), 58.0 (C₆), 55.2, 23.6 ((CH₂)₂), 50.2 (C₁); HMRS calcd for C₂₁H₂₆NO₄ (M⁺ – C₉H₈N) 356.1861; found 356.1865; Anal. calcd for C₃₀H₃₄N₂O₄, H₂O: C, 71.42, H, 7.14, N, 5.55; found: C, 71.68, H, 6.96, N, 5.63.

3,4-Di-O-benzyl-1,6-dideoxy-1,6-[2'-(1H-indol-3-yl)-ethyl]-imino-D-mannitol (20f). [α]_D – 4 (c 0.9, CHCl₃); ¹H

NMR 8.06 (s, 1 H, NH), 7.54 (d, 1 H, H indol), 7.30–6.96 (m, 14 H, Ar), 4.72–4.60 (AB, 4 H, OCH₂Ph), 4.08 (m, 2 H, H₂), 3.77 (s, 2 H, H₃), 2.93 (dd, 2 H, H₁), 2.92–2.85 (m, 4 H, (CH₂)₂), 2.80 (dd, 2 H, H_{1'}), ²J_{A,B} = 12, ²J_{1,1'} = 13, ³J_{1,2} = 3, ³J_{1',2} = 6; ¹³C NMR 138.3, 136.2, 128.4, 128.3, 127.8, 127.6, 127.2, 121.9, 121.6, 118.9, 118.4, 113.2, 111.3 (Ar), 80.8 (C₃), 73.1 (OCH₂Ph), 68.5 (C₂), 59.4, 23.0 ((CH₂)₂), 56.6 (C₁); HMRS calcd for C₂₁H₂₆NO₄ (M⁺–C₉H₈N) 356.1861; found 356.1861.

1-Deoxynojirimycin (4). Palladium black (120 mg) in acetic acid (3 mL) was completely hydrogenated prior to the addition of **4a** (300 mg, 0.69 mmol) in AcOH (2 mL). After 18 h stirring, the catalyst was removed by filtration through a celite pad and rinsed with AcOH. Concentration in vacuo and purification of the residue by ion-exchange chromatography (DOWEX 50 × 8, 50–100 mesh, elute with aqueous ammonia (1%)) afforded 113 mg (100%) of **4**. Mp 194–196 °C, [α]_D +46 (c 0.9, H₂O); lit⁸ mp 196 °C, [α]_D +47 (H₂O); ¹H NMR (D₂O) 3.82 (dd, 1 H, H₆), 3.62 (dd, 1 H, H_{6'}), 3.48 (ddd, 1 H, H₂), 3.31 (t, 1 H, H₃), 3.22 (t, 1 H, H₄), 3.12 (dd, 1 H, H_{1e}), 2.56 (m, 1 H, H₅), 2.46 (dd, 1 H, H_{1a}), ²J_{1a,1e} = 13, ³J_{1e,2} = 5, ³J_{1a,2} = 11, ³J_{3,4} = ³J_{4,5} = ³J_{3,2} = 9, ³J_{6,5} = 2.5, ³J_{6',5} = 6, ²J_{6,6'} = 11.5; ¹³C NMR (D₂O) 80.7, 73.8, 73.2 (C₂₋₄), 63.7 (C₆), 62.9 (C₅), 51.0 (C₁); HMRS calcd for C₅H₁₀NO₃ (M⁺–CH₂OH) 132.0660; found 132.0660.

1,5-Dideoxy-1,5-imino-L-gulitol (16). Hydrogenolysis of **16a** was carried out under identical conditions as for **4a** described above (100%). [α]_D +9 (c 0.6, H₂O); ¹H NMR (D₂O) 4.05 (ddd, 1 H, H₂), 3.96 (br s, 2 H, H_{3,4}), 3.70 (m, 2 H, H_{6,6'}), 3.20 (t, 1 H, H₅), 3.05 (dd, 1 H, H_{1e}), 2.87 (dd, 1 H, H_{1a}), ³J_{1e,2} = 4.5, ³J_{2,1a} = 11, ³J_{2,3} = 2, ³J_{5,6} = ³J_{5,6'} = 6, ²J_{1e,1a} = 12.5; ¹³C NMR (D₂O) 71.8, 70.7, 66.6 (C₂₋₄), 62.4 (C₆), 57.1 (C₅), 45.7 (C₁); HMRS calcd for C₅H₁₀NO₃ (M⁺–CH₂OH) 132.0660; found 132.0660.

1,6-Dideoxy-1,6-imino-D-mannitol (17). Hydrogenolysis of **17a** was carried out under identical conditions as for **4a** described above (100%). Mp 183–185 °C; [α]_D –38 (c 0.5, H₂O); ¹H NMR (D₂O) 4.05 (m, 2 H, H₂), 3.90 (s, 2 H, H₃), 2.93 (dd, 2 H, H₁), 2.84 (dd, 2 H, H_{1'}), ³J_{1,2} = 3.5, ³J_{1',2} = 6, ²J_{1,1'} = 14; ¹³C NMR (D₂O) 75.7, 73.1 (C_{2,3}), 51.1 (C₁); MS (CI, NH₃) 164 (M⁺+1).

1,6-Dideoxy-1,6-imino-L-iditol (18). Hydrogenolysis of **18a** was carried out under identical conditions as for **4a** described above (100%). [α]_D +20 (c 0.8, H₂O), lit³⁸ +19.9 (c 2, H₂O); ¹H NMR (D₂O) 3.70 (m, 2 H, H₂), 3.49 (dd, 2 H, H₃), 3.04 (dd, 2 H, H₁), 2.77 (dd, 2 H, H_{1'}), ³J_{1,2} = 4, ³J_{1',2} = 7.5, ²J_{1,1'} = 14, ³J_{2,3} = 5.5, ³J_{3,4} = 1.5; ¹³C NMR (D₂O) 77.9, 74.8 (C_{2,3}), 53.6 (C₁); MS (CI, NH₃) 164 (M⁺+1).

Isomerization of the piperidine **16a**

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-2,6-di-O-methanesulfonyl-L-gulitol (21). To a stirred solution of **16a** (100 mg, 0.23 mmol) in CH₂Cl₂ (1.5 mL) at 0 °C

was added NEt₃ (128 μL, 0.92 mmol) followed by methanesulfonyl chloride (42 mL, 0.53 mmol). After 10 min at 0 °C, the reaction was quenched by addition of water (7 mL) and diluted with CH₂Cl₂ (15 mL). After decantation and extraction (4 × 10 mL), the combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The crude **21** was used in the next step without further purification. ¹H NMR 7.30 (m, 15 H, Ph), 5.0 (m, 1 H, H₂), 4.71–4.53 (m, 4 H, OCH₂Ph), 4.43 (m 2 H, H_{6,6'}), 3.96 (dd, 1 H, H₄), 3.83 (s, 2 H, NCH₂Ph), 3.69 (dd, 1 H, H₃), 3.40 (m, 1 H, H₅), 3.11 (m, 1 H, H₁), 2.94 (m, 1 H, H_{1'}), 2.86, 2.82 (2s, 6H, MeSO₂), ³J_{3,4} = 8.5, ³J_{4,5} = 5, ³J_{2,3} = 3.

Reaction of the dimesylated piperidine **21 with cesium acetate.** To a stirred solution of **21** (130 mg, 0.22 mmol) in DMF (1 mL) was added AcOCs (423 mg, 2.2 mmol). After 24 h stirring at 40–50 °C, the mixture was concentrated in vacuo and diluted with CH₂Cl₂ (15 mL) and water (10 mL). After decantation and extraction (3 × 20 mL), the combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The resulting residue was dissolved in MeOH (1 mL) and K₂CO₃ (311 mg, 2.2 mmol) was added. After 1 h stirring at 20 °C, the reaction mixture was concentrated in vacuo, and diluted with CH₂Cl₂ (15 mL) and water (10 mL). After decantation and extraction (3 × 20 mL), the combined organic layers were washed with brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography (CH₂Cl₂:acetone, 92:8) afforded 43 mg (45%) of **22a** (R_f 0.35), 17 mg (18%) of **16a** (R_f 0.30) and 8 mg (8%) of **17a** (R_f 0.25).

N-Benzyl-3,4-di-O-benzyl-2,5-dideoxy-2,5-imino-L-iditol (22a). [α]_D –19 (c 0.7, CHCl₃); ¹H NMR 7.30 (m, 15 H, Ph), 4.66, 4.59 (AB, 4 H, OCH₂Ph), 4.36 (m, 2 H, H₃), 3.97, 3.90 (AB, 2 H, NCH₂Ph), 3.74 (dd, 2 H, H₁), 3.67 (dd, 2 H, H_{1'}), 3.40 (m, 2 H, H₂), ²J_{A,B} (OCH₂Ph) = 11.5, ²J_{A,B} (NCH₂Ph) = 14, ³J_{1,2} = 4.5, ³J_{1',2} = 2.5, ²J_{1,1'} = 12; ¹³C NMR 138.7, 137.8, 128.5, 128.1, 127.9, 127.7, 127.1 (Ph), 84.4 (C₃), 73.0 (OCH₂Ph), 61.5 (C₂), 59.4 (C₁), 52.4 (NCH₂Ph).

2,5-Dideoxy-2,5-imino-L-iditol (22). Hydrogenolysis of **22a** was carried out under identical conditions as for **4a** described above (100%). [α]_D +8 (c 0.6, H₂O), lit²⁴ +9.6 (c 0.6, H₂O); ¹H NMR (D₂O) 4.33 (d, 2 H, H₃), 3.90–3.75 (m, 6 H, H_{1,1',2}); ¹³C NMR (D₂O) 78.5 (C₃), 64.3 (C₂); 61.7 (C₁); MS (CI, NH₃) 164 (M⁺+1), HRMS calcd for C₅H₁₀NO₃ (M⁺–CH₂OH) 132.0660; found 132.0660.

Mitsunobu reaction with **16a.** To a solution of Ph₃P (448 mg, 1.708 mmol) in THF (4 mL) at 0 °C was dropwise added diethyl azodicarboxylate (DEAD) (270 μL, 1.708 mmol). After 5 min stirring, benzoic acid (208 mg, 1.708 mmol) in THF (500 μL) and **16a** (185 mg, 0.427 mmol) in THF (1 mL) were successively added dropwise. The reaction mixture was stirred for 15 h at 0 °C. If the reaction was not complete (monitoring by TLC), one equivalent or more of each

reagent was added. The reaction mixture was then concentrated in vacuo. The residue dissolved in AcOEt was filtered through a silica pad. Concentration in vacuo followed by flash chromatography (cyclohexane:AcOEt, 85:15) afforded a mixture of **22c** and **23b** (232 mg). To a solution of this mixture in MeOH (5 mL) was added K_2CO_3 (523 mg, 3.76 mmol). After, 5 h stirring at 20 °C, the reaction mixture was concentrated in vacuo. The residue was diluted with CH_2Cl_2 (30 mL) and water (10 mL). After decantation and extraction (3 \times 30 mL), the combined organic layers were washed with brine, dried (Na_2SO_4), and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 1:1) afforded 129 mg (70%) of **23a** (R_f 0.35) and 33 mg (18%) of **22a** (R_f 0.30).

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-L-iditol (23a). $[\alpha]_D +21$ (c 0.5, $CHCl_3$); 1H NMR 7.30 (m, 15 H, Ph), 4.83–4.54 (m, 4 H, OCH_2Ph), 3.95–3.57 (m, 7 H, $H_{2,3,4,6,6',NCH_2Ph}$), 3.03 (m, 1 H, H_5), 2.75–2.57 (m, 2 H, $H_{1,1'}$); ^{13}C NMR 138.7, 138.4, 137.4, 128.8, 128.7, 128.5, 128.3, 128.0, 127.9, 127.4 (Ph), 79.7, 79.2 ($C_{3,4}$), 74.2, 72.8 (OCH_2Ph), 68.0 (C_2), 60.3 (C_5), 59.2 (C_6), 58.4 (NCH_2Ph), 50.4 (C_1); HRMS calcd for $C_{26}H_{28}NO_3$ ($M^+ - CH_2OH$) 402.2069; found 402.2066.

1,5-Dideoxy-1,5-imino-L-iditol (23). Hydrogenolysis of **23a** was carried out under identical conditions as for **4a** described above (100%). $[\alpha]_D -24$ (c 0.7, H_2O); 1H NMR (D_2O) 3.84–3.75 (m, 3 H, $H_{4,6,6'}$), 3.66 (m, 2 H, $H_{2,3}$), 3.24 (m, 1 H, H_5), 3.04 (br d, 1 H, H_1), 2.82 (dd, 2 H, $H_{1'}$), $^2J_{1,1'} = 12.5$, $^3J_{1',2} = 6$; ^{13}C NMR (D_2O) 75.0, 73.3, 72.7 (C_{2-4}), 60.6 (C_6), 59.2 (C_5), 46.9 (C_1); HMRS calcd for $C_5H_{10}NO_3$ ($M^+ - CH_2OH$) 132.0660; found 132.0660.

Isomerization of the piperidine **4a**

N-Benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-2,6-di-O-methanesulfonyl-D-glucitol (24). Mesylation of **4a** was carried out under identical conditions as for **16a** described above (100%). 1H NMR 7.30 (m, 15 H, Ph), 4.96–4.67 (m, 4 H, OCH_2Ph), 4.58–4.43 (m 3 H, $H_{6,6',2}$), 4.06 (AB, 1 H, NCH_2Ph), 3.70–3.55 (m, 2 H, $H_{3,4}$), 3.51 (AB, 1 H, NCH_2Ph), 3.23 (dd, 1 H, H_{1e}), 2.87, 2.78 (2s, 6H, $MeSO_2$), 2.60 (m, 1 H, H_5), 2.34 (t, 1 H, H_{1a}), $^2J_{A,B} = 14$, $^3J_{1e,2} = 5$, $^3J_{1a,2} = ^2J_{1e,1a} = 11$.

Reaction of the dimesylated piperidine **24 with cesium acetate.** To a stirred solution of **24** (145 mg, 0.246 mmol) in DMF (3 mL) was added AcOCs (472 mg, 2.46 mmol). After 24 h stirring at 35 °C, the mixture was concentrated in vacuo. Then water (7 mL) and CH_2Cl_2 (15 mL) were added, and after decantation and extraction (4 \times 15 mL), the combined organic layers were washed with brine, dried (Na_2SO_4), and concentrated in vacuo. Flash chromatography (CH_2Cl_2 :acetone, 99:1) afforded 65 mg (51%) of **1b** (R_f 0.35) and 40 mg (31%) of **4b** (R_f 0.30). This latter gives **4a** by methanolysis.

1,6-Di-O-acetyl-N-benzyl-3,4-di-O-benzyl-2,5-dideoxy-2,5-imino-D-mannitol (1b). $[\alpha]_D -17$ (c 1.2, $CHCl_3$); 1H NMR 7.31 (m, 15 H, Ph), 4.53, 4.48 (AB, 4 H, OCH_2Ph), 4.22 (dd, 2 H, $H_{1'}$), 4.16 (dd, 2 H, $H_{1'}$), 4.07 (AB, 1 H, NCH_2Ph), 3.92 (br s, 2 H, H_3), 3.85 (AB, 1 H, NCH_2Ph), 3.35 (m, 2 H, H_2), 1.96 (s, 6 H, Ac), $^2J_{A,B} (NCH_2Ph) = 14$, $^2J_{A,B} (OCH_2Ph) = 12$, $^3J_{1,2} = 5$, $^3J_{1',2} = 6$, $^2J_{1,1'} = 11.5$; ^{13}C NMR 170.7 (CO), 138.9, 137.9, 128.4, 127.9, 127.7, 126.9 (Ph), 84.8 (C_3), 71.6 (OCH_2Ph), 64.2 (C_2), 63.0 (C_1), 51.3 (NCH_2Ph), 20.9 (CH_3CO).

2,6-Di-O-acetyl-N-benzyl-3,4-di-O-benzyl-1,5-dideoxy-1,5-imino-D-glucitol (4b). $[\alpha]_D +20$ (c 1.1, $CHCl_3$); 1H NMR 7.27 (m, 15 H, Ph), 4.93 (dt 1 H, H_2), 4.89–4.54 (m, 4 H, OCH_2Ph), 4.56 (m, 1 H, H_6), 4.28 (dd, 1 H, $H_{6'}$), 4.00 (AB, 1 H, NCH_2Ph), 3.63 (t, 1 H, H_4), 3.52 (t, 1 H, H_3), 3.33 (AB, 1 H, NCH_2Ph), 2.95 (dd, 1 H, H_1), 2.51 (br d, 1 H, H_5), 2.00 (m, 1 H, $H_{1'}$), 2.00, 1.86 (2s, 6 H, Ac), $^2J_{A,B} = 13.5$, $^2J_{6,6'} = 12$, $^2J_{1,1'} = 11$, $^3J_{6',5} = 1$, $^3J_{3,4} = ^3J_{2,3} = ^3J_{4,5} = 9$, $^3J_{2,1} = ^3J_{2,1'} = 4.5$.

N-Benzyl-3,4-di-O-benzyl-2,5-dideoxy-2,5-imino-D-mannitol (1a). To a stirred solution of **1b** (64 mg, 0.123 mmol) in MeOH (2 mL) was added K_2CO_3 (85 mg, 0.619 mmol). After 30 min stirring at 20 °C, the reaction mixture was concentrated in vacuo, then water (7 mL) and CH_2Cl_2 (20 mL) were added. After decantation and extraction (3 \times 15 mL), the combined organic layers were washed with brine, dried (Na_2SO_4), and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 1:1) afforded 53 mg (100%) of **1a** (R_f 0.3). **1a** can also be obtained, in a higher yield, by Mitsunobu reaction with **4a** and subsequently methanolysis, see below. $[\alpha]_D -5$ (c 0.9, $CHCl_3$); 1H NMR 7.31 (m, 15 H, Ph), 4.56, 4.50 (AB, 4 H, OCH_2Ph), 4.01 (br s, 2 H, H_3), 3.97 (br s, 2 H, NCH_2Ph), 3.79 (dd, 2 H, H_1), 3.58 (br d, 2 H, $H_{1'}$), 3.34 (m, 2 H, H_2), $^2J_{A,B} = 13$, $^3J_{1,2} = 3$, $^2J_{1,1'} = 11$; ^{13}C NMR 139.0, 137.3, 128.4, 128.0, 127.9, 127.7, 127.0 (Ph), 84.8 (C_3), 71.5 (OCH_2Ph), 67.9 (C_2), 61.0 (C_1), 51.0 (NCH_2Ph).

2,5-Dideoxy-2,5-imino-D-mannitol (1). Hydrogenolysis of **1a** was carried out under identical conditions as for **4a** described above (100%). Mp 112–114 °C, $[\alpha]_D +54$ (c 0.5, H_2O), lit^{25a} mp 115–117 °C, $[\alpha]_D +53.8$ (c 0.32, H_2O); 1H NMR (D_2O) 3.92 (m, 2 H, H_3), 3.80 (dd, 2 H, H_1), 3.71 (dd, 2 H, $H_{1'}$), 3.16 (m, 2 H, H_2), $^3J_{1,2} = 4$, $^3J_{1',2} = 6$, $^2J_{1,1'} = 11$; ^{13}C NMR (D_2O) 80.2 (C_3), 64.6 (C_2), 64.3 (C_1); MS (CI, NH_3) 164 ($M^+ + 1$), HRMS calcd for $C_5H_{10}NO_3$ ($M^+ - CH_2OH$) 132.0660; found 132.0660.

Mitsunobu reaction with **4a.** Mitsunobu reaction with **4a** (140 mg, 0.323 mmol) was carried out under identical conditions as for **16a** described above, to give after flash chromatography (cyclohexane:AcOEt, 85:15) 128 mg (64%) of **1c** (R_f 0.35) and 58 mg (29%) of **4c** (R_f 0.30). By methanolysis, as above, **1c** (or **4c**) gives **1a** (or **4a**).

***N*-Benzyl-1,6-di-*O*-benzoyl-3,4-di-*O*-benzyl-2,5-dideoxy-2,5-imino-D-mannitol (1c).** $[\alpha]_D -26$ (*c* 0.9, CHCl₃); ¹H NMR 7.96 (d, 4 H, Ph), 7.51–7.20 (m, 21 H, Ph), 4.54 (s, 4 H, OCH₂Ph), 4.51 (dd 2 H, H₁), 4.41 (dd, 2 H, H_{1'}), 4.19 (AB, 1 H, NCH₂Ph), 4.12 (br s, 2 H, H₃), 3.93 (AB, 1 H, NCH₂Ph), 3.56 (m, 2 H, H₂), ²*J*_{A,B} = 14, ³*J*_{1,2} = 5.5, ³*J*_{1',2} = 4, ²*J*_{1,1'} = 11; ¹³C NMR 166.4 (CO), 138.8, 137.9, 132.9, 130.0, 129.7, 128.4, 128.3, 128.0, 127.7, 127.0 (Ph), 85.2 (C₃), 71.7 (OCH₂Ph), 64.4 (C₂), 63.5 (C₁), 51.3 (NCH₂Ph).

***N*-Benzyl-2,6-di-*O*-benzoyl-3,4-di-*O*-benzyl-1,5-dideoxy-1,5-imino-D-glucitol (4c).** $[\alpha]_D +38$ (*c* 1.0, CHCl₃); ¹H NMR 8.05 (d, 2 H, Ph), 7.95 (d, 2 H, Ph), 7.65–7.17 (m, 21 H, Ph), 5.30 (m, 1 H, H₂), 4.95–4.80 (m, 2 H, H_{6,6'}), 4.80–4.56 (m, 4 H, OCH₂Ph), 4.17 (AB, 1 H, NCH₂Ph), 3.86 (t, 1 H, H₄), 3.77 (t, 1 H, H₃), 3.46 (d, 1 H, NCH₂Ph), 3.16 (dd, 1 H, H₁), 2.76 (br d, 1 H, H₅), 2.26 (t, 1 H, H_{1'}), ³*J*_{3,4} = ³*J*_{4,5} = ²*J*_{2,3} = 8, ³*J*_{1',2} = ²*J*_{1,1'} = 10, ³*J*_{1,2} = 4, ²*J*_{A,B} = 14.

Azasugars via the *N*-benzyloxycarbonyl piperidine 4e

3,4-Di-*O*-benzyl-1,5-dideoxy-1,5-imino-D-glucitol (4d). Palladium hydroxide (20%, 400 mg) in absolute EtOH (8 mL) was completely hydrogenated prior to the addition of **4a** (1.05 g, 2.42 mmol) in absolute EtOH (3 mL). After 2.5 h stirring, the catalyst was removed by filtration through a celite pad and the organic layer was concentrated in vacuo to afford crude **4d** (100%). It was used in the next step without further purification. ¹H NMR 7.30 (m, 10 H, Ph), 4.98–4.62 (m, 4 H, OCH₂Ph), 3.75–3.50 (m, 3 H, H_{2,4,6}), 3.36 (m, 2 H, H_{3,6'}), 3.17 (dd, 1 H, H₁), 2.65 (m, 1 H, H₅), 2.51 (t, 1 H, H_{1'}), ³*J*_{1',2} = ²*J*_{1,1'} = 11, ³*J*_{1,2} = 4; ¹³C NMR 138.5, 138.0, 128.5, 128.4, 127.9, 127.8 (Ph), 87.1, 79.3 (C_{3,4}), 75.2, 74.9 (OCH₂Ph), 71.2 (C₂), 61.7 (C₆), 61.0 (C₅), 49.1 (C₁).

***N*-Benzyloxycarbonyl-3,4-di-*O*-benzyl-1,5-dideoxy-1,5-imino-D-glucitol (4e).** To a solution of **4d** (831 mg, 2.42 mmol) in DMF was added K₂CO₃ (434 mg, 3.15 mmol). The mixture was cooled to 0 °C and benzyldichloroformate (385 μL, 2.66 mmol) was added dropwise. After 30 min stirring at 0 °C, the reaction mixture was filtered through a celite pad and the organic layer was concentrated in vacuo. The residue was diluted in CH₂Cl₂ (40 mL) and washed with brine. The organic layer was dried (Na₂SO₄) and concentrated in vacuo. Flash chromatography (AcOEt:cyclohexane, 6:4) afforded 1.05 g (90%) of **4e** (*R*_f 0.35). $[\alpha]_D -46$ (*c* 0.7, CHCl₃); ¹H NMR 7.30 (m, 15 H, Ph), 5.16 (s, 2 H, CO₂CH₂Ph), 4.66 (m, 1 H, H₅), 4.63–4.43 (m, 4 H, OCH₂Ph), 4.17 (br d, 1 H, H₁), 3.91 (dd, 1 H, H₆), 3.80–3.53 (m, 4 H, H_{6',2,3,4}), 3.43 (d, 1 H, H_{1'}), ²*J*_{1,1'} = 14, ³*J*_{6,5} = 7.5, ²*J*_{6,6'} = 11; ¹³C NMR 157.2 (CO), 137.1 136.6, 136.4, 129.6, 128.6, 128.5, 128.4, 128.1, 127.9, 127.8, 127.7, 127.6 (Ph), 74.1, 73.8 (C_{3,4}), 72.5, 71.7 (OCH₂Ph), 67.4 (CO₂CH₂Ph), 66.3 (C₂), 60.7 (C₆), 55.2 (C₅), 42.5 (C₁); Anal. calcd for C₂₈H₃₁NO₆: C, 70.42, H, 6.54, N, 2.93; found: C, 70.34, H, 6.56, N, 2.87.

***N*-Benzyloxycarbonyl-3,4-di-*O*-benzyl-2,6-di-*O*-benzoyl-1,5-dideoxy-1,5-imino-D-mannitol (25).** Mitsunobu reaction with **4e** (100 mg, 0.21 mmol) in presence of 4 equiv of [Ph₃P–DEAD–PhCO₂H] was carried out under identical conditions as for **16a** described above to give 131 mg (91%) of **25** (*R*_f 0.30, cyclohexane: AcOEt, 85:15). $[\alpha]_D -2$ (*c* 1.6, CHCl₃); ¹H NMR 8.02 (d, 2 H, Ph), 7.91 (d, 2 H, Ph), 7.60–7.17 (m, 21 H, Ph), 5.39 (br d, 1 H, H₂), 5.20–4.95 (m, 2 H, CO₂CH₂Ph), 4.88 (m, 1 H, H₅), 4.76 (t, 1 H, H₆), 4.64–4.45 (m, 4 H, OCH₂Ph), 4.45 (dd, 1 H, H_{6'}), 4.41–4.28 (m, 1 H, H_{1e}), 4.12 (m, 1 H, H₃), 3.74 (m, 1 H, H₄), 3.52 (t, 1 H, H_{1a}), ³*J*_{6,5} = ²*J*_{6,6'} = 10, ³*J*_{6',5'} = 6, ³*J*_{1a,2} = ²*J*_{1e,1a} = 12; ¹³C NMR 166.1, 165.3 (CO), 155.9 (NCO), 137.4 137.3, 136.3, 133.2, 132.9, 129.8, 129.7 129.6, 128.4, 127.8, 127.6 (Ph), 74.3, 73.3 (C_{3,4}), 73.7, 71.1 (OCH₂Ph), 68.2 (C₂), 67.5 (C₆), 61.6 (CO₂CH₂Ph), 52.8, 52.0 (C₅), 37.5 (C₁).

3,4-Di-*O*-benzyl-1,5-dideoxy-1,5-imino-D-mannitol (5a). A mixture of **25** (85 mg, 0.123 mmol) and K₂CO₃ (256 mg, 1.84 mmol) in MeOH (4 mL), in a 20 mL flask, was concentrated in vacuo at 40 °C for 20 min. The reaction was monitored by TLC (CH₂Cl₂:MeOH, 85:15, *R*_f 0.9, *R*_f 0.35 for **25** and **5a**, respectively). If the reaction was not complete, the residue was diluted with MeOH and concentrated again in vacuo. The residue was then diluted with CH₂Cl₂ (20 mL) and water (8 mL). After decantation and extraction (4 × 15 mL), the combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. Flash chromatography (CH₂Cl₂:MeOH, 85:15) afforded 40 mg (95%) of **5a**. $[\alpha]_D +3$ (*c* 0.9, CHCl₃); ¹H NMR 7.30 (m, 10 H, Ph), 4.89–4.56 (m, 4 H, OCH₂Ph), 4.02 (br s, 1 H, H₂), 3.80 (dd, 1 H, H₆), 3.60 (dd, 1 H, H_{6'}), 3.39–3.48 (m, 2 H, H_{4,3}), 3.16 (dd, 1 H, H₁), 2.63 (d, 1 H, H_{1'}), 2.50 (m, 1 H, H₅), ³*J*_{6,5} = 3, ³*J*_{6',5'} = 5, ²*J*_{6,6'} = 11, ³*J*_{1,2} = 2, ²*J*_{1,1'} = 14; ¹³C NMR 138.4 137.9, 128.5, 128.4, 128.0, 127.8, 127.7 (Ph), 83.6, 76.3 (C_{3,4}), 75.1, 71.7 (OCH₂Ph), 66.9 (C₂), 61.9 (C₆), 61.1 (C₅), 48.5 (C₁); HMRS calcd for C₁₉H₂₂NO₃ (M⁺ – CH₂OH) 312.1599; found 312.1598.

1-Deoxymannojirimycin (5). Hydrogenolysis of **5a** was carried out under identical conditions as for **4a** described above (100%). Mp 185 °C, $[\alpha]_D -40$ (*c* 0.9, H₂O), lit.^{27d} mp 185–187 °C, $[\alpha]_D -39$ (H₂O); ¹H NMR (D₂O) 4.08 (m, 1 H, H₂), 3.83 (m, 2 H, H_{6,6'}), 3.69 (t, 1 H, H₄), 3.62 (dd, 1 H, H₃), 3.12 (br d, 1 H, H₁), 2.88 (d, 1 H, H_{1'}), 2.64 (m, 1 H, H₅), ³*J*_{3,4} = ³*J*_{4,5} = 9.7, ³*J*_{2,3} = 3, ²*J*_{1,1'} = 14; ¹³C NMR (D₂O) 77.0, 71.5, 70.7 (C_{2,4}), 63.3 (C₅), 63.1 (C₆), 51.0 (C₁); MS (CI, NH₃) 164 (M⁺ + 1); HRMS calcd for C₅H₁₀NO₃ (M⁺ – CH₂OH) 132.0660; found 132.0660.

3,4-Di-*O*-benzyl-*N*,6-*O*-carbonyl-1,5-dideoxy-1,5-imino-D-glucitol (26). To a solution of **4e** (92 mg, 0.193 mmol) in MeOH (3 mL) was added K₂CO₃ (268 mg, 1.93 mmol). The reaction mixture was stirred for 45 min at 20 °C, and quenched by addition of water (7 mL), and diluted with CH₂Cl₂ (20 mL). After decantation and extraction (4 × 15 mL), the combined

organic layers were washed with brine, dried (Na_2SO_4) and concentrated in vacuo. Flash chromatography (AcOEt :cyclohexane, 65:35) afforded 68 mg (96%) of **26** (R_f 0.35). Mp 131 °C; $[\alpha]_D +113$ (c 1.0, CHCl_3); ^1H NMR 7.30 (m, 10 H, Ph), 4.98–4.58 (m, 4 H, OCH_2Ph), 4.24 (t, 1 H, H_6), 4.00 (dd, 1 H, H_{1e}), 3.73 (dd, 1 H, $\text{H}_{6'}$), 3.35 (m, 2 H, $\text{H}_{2,5}$), 3.40, 3.31 (2t, 2 H, $\text{H}_{3,4}$), 2.71 (t, 1 H, H_{1a}), $^3J_{3,4} = ^3J_{4,5} = ^3J_{2,3} = 9$, $^3J_{6,5} = ^2J_{6,6'} = 8$, $^3J_{6',5} = 4.5$, $^3J_{1e,2} = 5$, $^3J_{1a,2} = ^2J_{1e,1a} = 12$; ^{13}C NMR 156.7 (CO), 138.0, 137.4, 128.7, 128.3, 128.1, 127.9 (Ph), 86.4, 80.2 ($\text{C}_{3,4}$), 75.7, 74.9 (OCH_2Ph), 69.2 (C_2), 65.6 (C_6), 57.0 (C_5), 44.3 (C_1); HMRS calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_5$ ($M^+ - \text{C}_7\text{H}_7$) 278.1028; found 278.1030.

2-Azido-3,4-di-O-benzyl-N,6-O-carbonyl-1,2,5-trideoxy-1,5-imino-D-mannitol (27). To a solution of Ph_3P (127 mg, 0.486 mmol) in THF (1 mL) at 0 °C was dropwise added DEAD (77 μL , 0.486 mmol). After 5 min stirring, hydrazoic acid²⁸ (1.3 M in benzene, 374 μL , 0.486 mmol) and **26** (60 mg, 0.162 mmol) in THF (400 μL) were successively added dropwise. The reaction mixture was stirred for 1 h at 0 °C and 2 h at 20 °C. The reaction was monitored by TLC (CH_2Cl_2 :acetone, 85:15, R_f 0.4, R_f 0.9 for **26** and **27**, respectively). If the reaction was not complete, one equivalent or more of each reagent was added. The reaction mixture was then concentrated in vacuo. Flash chromatography (CH_2Cl_2 :acetone, 95:5) afforded 57 mg (90%) of **27** (R_f 0.25). $[\alpha]_D +50$ (c 0.6, CHCl_3); ^1H NMR 7.40–7.22 (m, 10 H, Ph), 4.96–4.61 (m, 4 H, OCH_2Ph), 4.26 (t, 1 H, H_6), 3.98 (m, 1 H, H_2), 3.90 (dd, 1 H, H_1), 3.81 (dd, 1 H, $\text{H}_{6'}$), 3.73 (t, 1 H, H_4), 3.66 (dd, 1 H, H_3), 3.47 (dt, 1 H, H_5), 2.93 (dd, 1 H, $\text{H}_{1'}$), $^3J_{3,4} = ^3J_{4,5} = 9$, $^3J_{2,3} = 2.5$, $^3J_{6,5} = ^2J_{6,6'} = 8.5$, $^3J_{6',5} = 4$, $^3J_{1,2} = 1.3$, $^3J_{1',2} = 0.6$, $^2J_{1,1'} = 14.5$; ^{13}C NMR 157.0 (CO), 137.6, 137.1, 128.6, 128.2, 127.9 (Ph), 82.7, 76.3 ($\text{C}_{3,4}$), 75.3, 72.5 (OCH_2Ph), 65.7 (C_6), 58.3, 57.0 ($\text{C}_{2,5}$), 43.2 (C_1); HMRS calcd for $\text{C}_{14}\text{H}_{15}\text{N}_4\text{O}_4$ ($M^+ - \text{C}_7\text{H}_7$) 303.1093; found 303.1093.

2-Azido-3,4-di-O-benzyl-1,2,5-trideoxy-1,5-imino-D-mannitol (28). Methanolysis of **27** was carried out under identical conditions as for **5a** described above (96%). R_f 0.4 (CH_2Cl_2 :MeOH, 85:15); $[\alpha]_D +4$ (c 0.9, CHCl_3); ^1H NMR 7.36–7.25 (m, 10 H, Ph), 4.91–4.59 (m, 4 H, OCH_2Ph), 3.91 (br s, 1 H, H_2), 3.75 (dd, 1 H, H_6), 3.68 (dd, 1 H, H_3), 3.63–3.56 (m, 2 H, $\text{H}_{4,6'}$), 3.03 (dd, 1 H, H_1), 2.65 (d, 1 H, $\text{H}_{1'}$), 2.53 (m, 1 H, H_5), $^3J_{3,4} = 9.5$, $^3J_{2,3} = 2.5$, $^3J_{6,5} = 2.5$, $^2J_{6,6'} = 11$, $^3J_{1,2} = 1$, $^2J_{1,1'} = 14$; ^{13}C NMR 138.2, 137.7, 128.5, 128.2, 127.8 (Ph), 83.8, 76.3 ($\text{C}_{3,4}$), 75.2, 72.3 (OCH_2Ph), 62.2 (C_6), 61.1, 60.3 ($\text{C}_{2,5}$), 47.4 (C_1); HMRS calcd for $\text{C}_{19}\text{H}_{21}\text{N}_4\text{O}_2$ ($M^+ - \text{CH}_2\text{OH}$) 337.1664; found 337.1664.

2-Amino-1,2,5-trideoxy-1,5-imino-D-mannitol (29). Hydrogenolysis of **28** was carried out under identical conditions as for **4a** described above (75%); $[\alpha]_D -14$ (c 0.4, H_2O); ^1H NMR (D_2O) 3.86 (br d, 1 H, H_6), 3.74 (dd, 1 H, $\text{H}_{6'}$), 3.70 (dd, 1 H, H_3), 3.53 (t, 1 H, H_4), 3.32 (m, 1 H, H_2), 3.05 (br d, 1 H, H_1), 2.89 (br d, 1 H, $\text{H}_{1'}$), 2.58 (m, 1 H, H_5), $^3J_{3,4} = ^3J_{4,5} = 9.5$, $^3J_{2,3} = 3.5$, $^2J_{6,6'} = 11$, $^3J_{6',5} = 5.5$, $^2J_{1,1'} = 14$; ^{13}C NMR (D_2O)

76.6, 71.0 ($\text{C}_{3,4}$), 63.9 (C_6); 63.8 (C_5), 53.9 (C_2), 49.9 (C_1); MS (CI, NH_3) 163 ($M^+ + 1$), HRMS calcd for $\text{C}_5\text{H}_{11}\text{N}_2\text{O}_2$ ($M^+ - \text{CH}_2\text{OH}$) 131.0820; found 131.0820.

(2S,3R,4R,5S)-N-Benzylloxycarbonyl-3,4-di-O-benzyl-3,4,5-trihydroxypipicollic acid (30a). To a stirred solution of **4e** (480 mg, 1 mmol) in diethylether (10 mL) was slowly added at 0 °C an aq solution of chromic acid (1.95 mL, 2 mmol).³⁰ After 1 h stirring at 0 °C, diethylether (20 mL) was added, and after decantation and extraction (4×20 mL Et_2O , then 4×30 mL CH_2Cl_2), the combined organic layers were dried (Na_2SO_4) and concentrated in vacuo. Flash chromatography (CH_2Cl_2 :MeOH, 92:8) afforded 246 mg (50%) of **30a** (R_f 0.3). ^1H NMR 7.25 (m, 15 H, Ph), 5.25–5.05 (m, 2 H, $\text{CO}_2\text{CH}_2\text{Ph}$), 4.9–4.0, 3.60 (2 m, 8 H and 2 H, OCH_2Ph , $\text{H}_{2,6'}$); ^{13}C NMR 174.6 (C_1), 158.5 (CO), 137.3, 136.6, 136.3, 128.6, 128.4, 128.1, 127.9, 127.8, 127.4 (Ph), 74.2, 72.9 ($\text{C}_{3,4}$), 72.0, 71.7 (OCH_2Ph), 67.7 ($\text{CO}_2\text{CH}_2\text{Ph}$), 66.9 (C_5), 55.2 (C_2), 44.4 (C_6); MS (CI, NH_3) 509 ($M^+ + 18$), 492 ($M^+ + 1$).

Methyl (2S,3R,4R,5S)-N-benzyl oxy carbonyl-3,4-di-O-benzyl-3,4,5-trihydroxy pipicolate (30b). To a solution of **30a** (50 mg, 0.102 mmol) in MeOH: CH_2Cl_2 (1:1, 4 mL) was slowly added a solution of CH_2N_2 in diethylether until the yellow colour of the mixture was maintained. After 5 min stirring, and in vacuo concentration, flash chromatography (cyclohexane:AcOEt, 6:4) afforded 51 mg (100%) of **30b** (R_f 0.3). $[\alpha]_D -9$ (c 0.7, CHCl_3); ^1H NMR (50 °C) 7.30 (m, 15 H, Ph), 5.29 (s, 1 H, H_2), 5.18 (m, 2 H, $\text{CO}_2\text{CH}_2\text{Ph}$), 4.78–4.13 (m, 5 H, OCH_2Ph , H_6), 3.80–3.55 (m, 4 H, $\text{H}_{5,3,4,6'}$), 3.50 (s, 3 H, CH_3); ^{13}C NMR mixture of atropoisomers 169.0 (C_1), 157.4, 156.5 (CO), 137.2, 136.5, 136.4, 128.6, 128.5, 128.4, 128.3, 128.0, 127.9, 127.6, 127.4 (Ph), 74.7, 74.5, 72.9, 72.6 ($\text{C}_{3,4}$), 72.2, 72.1, 71.8 (OCH_2Ph), 67.6 ($\text{CO}_2\text{CH}_2\text{Ph}$), 66.5 (C_5), 55.1, 54.2 (C_2), 52.2 (CH_3), 44.1, 43.8 (C_6); MS (CI, NH_3) 523 ($M^+ + 18$), 506 ($M^+ + 1$); Anal. calcd for $\text{C}_{29}\text{H}_{31}\text{NO}_7$: C, 68.90, H, 6.18, N, 2.77; found: C, 68.88, H, 6.25, N, 2.80.

(2S,3R,4R,5S)-3,4,5-trihydroxypipicollic acid (30). Hydrogenolysis of **30a** was carried out under identical conditions as for **4a** described above, to give **30** (100%). Mp 226 °C, lit^{31d} 228–230 °C; $[\alpha]_D +16$ (c 0.3, H_2O), lit^{31c} +14.1 (c 0.3, H_2O), ^{31c} +18.3 (c 1.0, H_2O), ^{31d} ^1H NMR (D_2O) 3.78 (m, 1 H, H_5), 3.68 (br t, 1 H, H_3), 3.53 (br t, 1 H, H_4), 3.48–3.40 (m, 2 H, $\text{H}_{2,6}$), 2.86 (br t, 1 H, $\text{H}_{6'}$), $^3J_{3,4} = ^3J_{2,3} = 10$, $^3J_{6',5} = ^2J_{6,6'} = 11$; ^{13}C NMR (D_2O) 174.9 (C_1), 78.6, 73.1, 69.9 (C_{3-5}), 64.0 (C_2), 48.1 (C_6); MS (CI, NH_3) 178 ($M^+ + 1$).

Isomerization of the azepane 17a or 18a

Mitsunobu reaction with 17a. To a solution of Ph_3P (55 mg, 0.213 mmol) in THF (500 μL) at 0 °C was dropwise added DEAD (34 μL , 0.213 mmol). After 5 min stirring, benzoic acid (26 mg, 0.213 mmol) in THF (200 μL) and **17a** (77 mg, 0.177 mmol) in THF

(300 μ L) were successively added dropwise. The reaction mixture was stirred for 10 min at 0 °C and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 7:3) afforded 65 mg of a mixture of **17b** and **16c**. Methanolysis of this mixture, as above, and flash chromatography (CH₂Cl₂:acetone 90:10) afforded 18 mg (24%) of **16a** (*R_f* 0.35) and 28 mg (36%) of **17a** (*R_f* 0.30).

Mitsunobu reaction with 18a. To a solution of Ph₃P (157 mg, 0.6 mmol) in THF (1.5 mL) at 0 °C was dropwise added DEAD (95 μ L, 0.6 mmol). After 5 min stirring, **18a** (200 mg, 0.462 mmol) in THF (500 μ L) was added dropwise. The reaction mixture was stirred for 2 h at 20 °C and concentrated in vacuo. Flash chromatography (cyclohexane:AcOEt, 4:1) afforded 181 mg (94%) of [1*R*-(6-*endo*,7-*exo*)]-6,7-di-*O*-benzyl-3-benzyl-8-oxa-3-azabicyclo-[3.2.1]-octane-6,7-diol **31a**. [α]_D – 32 (c 1, CHCl₃); ¹H NMR 7.35–7.10 (m, 15 H, Ph), 4.63–4.48 (m, 4 H, OCH₂Ph), 4.32 (d, 1 H, H₇), 4.23 (br d, 1 H, H₅), 4.16 (dd, 1 H, H₆), 4.10 (s, 1 H, H₁), 3.53, 3.44 (AB, 2 H, NCH₂Ph), 2.86 (d, 1 H, H_{4endo}), 2.65 (d, 1 H, H_{2endo}), 2.44 (dd, 1 H, H_{2exo}), 2.26 (dd, 1 H, H_{4exo}), ³*J*_{6,7} = 2.4, ³*J*_{6,5} = 6, ³*J*_{4exo,5} = 1, ³*J*_{2exo,1} = 0.8, ²*J*_{4exo,4endo} = 11.6, ²*J*_{2exo,2endo} = 11.2, ²*J*_{A,B} = 13; ¹³C NMR 138.2, 138.1, 138.0, 128.5, 128.3, 128.1, 127.8, 127.7, 127.6, 126.7 (Ph), 87.0, 86.3 (C_{6,7}), 79.1, 75.6 (C_{1,5}), 72.6, 71.4 (OCH₂Ph), 62.1 (NCH₂Ph), 56.0, 51.6 (C_{2,4}); Anal. calcd for C₂₇H₂₉NO₃: C, 78.04, H, 7.03, N, 3.37; found: C, 78.07, H, 7.06, N, 3.41.

[1*R*-(6-*endo*,7-*exo*)]-8-oxa-3-azabicyclo-[3.2.1]-octane-6,7-diol (31**).** Hydrogenolysis of **31a** was carried out under identical conditions as for **4a** described above (100%). [α]_D – 30 (c 0.8, MeOH), lit³³ – 4.4 (c 2.3, MeOH); ¹H NMR (CD₃OD) 4.24 (d, 1 H, H₆), 4.16 (br s, 1 H, H₇), 4.12 (br d, 1 H, H₅), 3.79 (br s, 1 H, H₁), 2.95 (br d, 1 H, H₄), 2.89 (br s, 1 H, H_{2,2'}), 2.78 (d, 1 H, H_{4'}), ³*J*_{6,5} = 6.4, ²*J*_{4,4'} = 13.2; ¹³C NMR (CD₃OD) 83.6, 82.8, 82.0, 79.2 (C_{6,7,1,5}), 48.4, 45.6 (C_{2,4}); HRMS calcd for C₆H₁₁NO₃ (*M*⁺) 145.0738; found 145.0739.

Partial hydrogenolysis of 31a. Palladium on charcoal (10%, 6 mg) in absolute EtOH (2 mL) was completely hydrogenated prior to the addition of **31a** (43 mg, 0.103 mmol) in absolute EtOH (1 mL). After 2 h stirring, the catalyst was removed by filtration through a celite pad and rinsed with EtOH. The organic layer was concentrated in vacuo. Flash chromatography (CH₂Cl₂:MeOH, 93:7) afforded 15 mg (43%) of **31b** (*R_f* 0.30) and 21 mg (55%) of **32** (*R_f* 0.95).

[1*R*-(6-*endo*,7-*exo*)]-6,7-Di-*O*-benzyl-8-oxa-3-azabicyclo-[3.2.1]-octane-6,7-diol (31b**).** [α]_D – 8 (c 0.7, CHCl₃), lit³³ – 6.4 (c 0.6, CHCl₃); ¹H NMR (C₆D₆) 7.20 (m, 10 H, Ph), 4.30 (m, 4 H, OCH₂Ph), 4.21 (br d, 1 H, H₆), 4.01 (br s, 2 H, H_{7,5}), 3.92 (br d, 1 H, H₁), 2.98 (d, 1 H, H_{4endo}), 2.93 (d, 1 H, H_{2endo}), 2.76 (d, 1 H, H_{2exo}), 2.32 (d, 1 H, H_{4exo}), ³*J*_{6,5} = 6, ²*J*_{4endo,4exo} = 2, ²*J*_{2endo,2exo} = 13; ¹³C NMR 137.7, 137.6, 128.4, 127.9 (Ph), 86.7, 86.0

(C_{6,7}), 79.2, 76.7 (C_{1,5}), 72.9, 71.4 (OCH₂Ph), 48.3, 45.1 (C_{2,4}); MS (CI, NH₃) 326 (*M*⁺ + 1).

[1*R*-(6-*endo*,7-*exo*)]-6,7-Di-*O*-benzyl-3-ethyl-8-oxa-3-azabicyclo-[3.2.1]-octane-6,7-diol (32**).** ¹H NMR 7.30 (m, 10 H, Ph), 4.59, 4.49 (2 s, 4 H, OCH₂Ph), 4.24 (br s, 1 H, H₇), 4.20 (br d, 1 H, H₅), 4.12 (dd, 1 H, H₆), 4.08 (s, 1 H, H₁), 2.86 (d, 1 H, H_{4endo}), 2.69 (d, 1 H, H_{2endo}), 2.43–2.32 (m, 3 H, H_{2exo}, CH₂), 2.20 (dd, 1 H, H_{4exo}), 1.03 (t, 3 H, CH₃), ³*J*_{6,5} = 6, ³*J*_{4,5} = 1.5, ²*J*_{4endo,4exo} = 11.5, ²*J*_{2endo,2exo} = 11.3, ³*J*_{4exo,5} = 1; MS (CI, NH₃) 354 (*M*⁺ + 1).

Inhibition analysis. α -D-Glucosidase from *Bacillus stearothermophilus*, β -D-glucosidase from almonds, α -D-mannosidase from Jack bean and α -L-fucosidase from bovine kidney were purchased from Sigma. *K_i* determinations were run at 37 °C using the corresponding *p*-nitrophenyl- α - (or β)-glycoside at the optimum pHs (citrate-phosphate buffer of pH 6.8, 5.0, 4.5 and 5.5 for α -D-glucosidase, β -D-glucosidase, α -D-mannosidase and α -L-fucosidase, respectively). For the inhibition studies, inhibitors were incorporated variously into each buffer to give a final concentration in the range 10^{–7}–10^{–3} mol L^{–1}. Dissociation constants for inhibition were calculated from the slopes of plots 1/ ν against 1/[*S*] from the rates of substrate hydrolysis in the absence and presence of inhibitor (Lineweaver–Burk plots).

Acknowledgements

This work was part of the Bio Avenir programme supported by Rhône-Poulenc with the participation of the French Ministry of Research and the French Ministry of Industry. One of us (L.P.) thanks the CNRS and Rhône-Poulenc for a grant.

References

- (a) Look, G. C.; Fotsch, C. H.; Wong, C.-H. *Acc. Chem. Res.* **1993**, *26*, 182. (b) Winchester, B.; Fleet, G. W. J. *Glycobiology* **1992**, *2*, 199, and refs cited therein.
- Anzeveno, P. B.; Creemer, L. J.; Daniel, J. K.; King, C.-H. R.; Liu, P. S. J. *Org. Chem.* **1989**, *54*, 2539, and refs cited therein.
- Woyrnarowska, B.; Wilkiel, H.; Sharma, M.; Carpenter, N.; Fleet, G. W. J.; Bernacki, R. J. *Anticancer Res.* **1992**, *12*, 161, and refs cited therein.
- (a) Karpas, A.; Fleet, G. W. J.; Dwek, R. A.; Petrusson, S.; Namgoong, S. K.; Ramsden, N. G.; Jacob, G. S.; Rademacher, T. W. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 9229. (b) Fleet, G. W. J.; Karpas, A.; Raymond, A. D.; Fellows, L. E.; Tysms, A. S.; Peterson, S.; Namgoong, S. K.; Ramsden, N. O.; Smith, P. W.; Son, J. C.; Wilson, F.; Witty, D. R.; Jacob, G. S.; Rademacher, T. W. *FEBS Lett.* **1988**, *237*, 128, and refs cited therein.
- Welter, A.; Jadot, J.; Dardenne, G.; Marlier, M.; Casimir, J. *Phytochemistry* **1976**, *15*, 747.

6. Furukawa, J.; Okuda, S.; Saito, K.; Hatanoka, S. *Phytochemistry* **1985**, *24*, 593.
7. Baku, A.; Faulstich, H.; Wieland, T.; Dabrowski, J. *Proc. Natl. Acad. Sci. U.S.A.* **1980**, *77*, 2370.
8. Inouye, S.; Tsuruoka, T.; Ito, T.; Niida, T. *Tetrahedron* **1968**, *23*, 2125.
9. Fellows, L. E.; Bell, E. A.; Lynn, D. G.; Pilkievicz, F.; Miura, I.; Nakanishi, K. *J. Chem. Soc. Chem. Commun.* **1979**, 977.
10. Miyake, Y.; Ebata, M. *Agric. Biol. Chem.* **1988**, *23*, 2125.
11. Colegate, S. M.; Dorling, P. R.; Huxtable, C. R. *Aust. J. Chem.* **1979**, *32*, 2257.
12. Hohenschutz, L. D.; Bell, E. A.; Jewess, P. J.; Leworthy, P.; Pryce, R. J.; Arnold, E.; Clardy, J. *Phytochemistry* **1981**, *20*, 811.
13. Tropea, J. E.; Molyneux, R. J.; Kaushal, G. P.; Pan, Y. T.; Mitchell, M.; Elbein, A. D. *Biochemistry* **1989**, *28*, 2027, and refs cited therein.
14. Baldwin, J. E.; *J. Chem. Soc., Chem. Commun.* **1976**, 734.
15. Poitout, L.; Thesis, Université Pierre et Marie Curie, Paris, 1995.
16. Poitout, L.; Le Merrer, Y.; Depezay, J.-C. *Tetrahedron Lett.* **1994**, *35*, 3293; *Tetrahedron Lett.* **1996**, *37*, 1609; *Tetrahedron Lett.* **1996**, *37*, 1613.
17. Jurczak, J.; Bauer, T.; Chmielewski, M. *Carbohydr. Res.* **1987**, *164*, 493.
18. Mitsunobu, O. *Synthesis* **1981**, 1. Hughes, D. L. *Org. React.* **1992**, *42*, 335.
19. Ganem has reported the cyclization of a monoepoxy amine to furnish a mixture of six- and seven-membered azasugars in nearly a 1:1 ratio, Bernotas, R. C.; Ganem, B. *Tetrahedron Lett.* **1984**, *25*, 165.
20. Lohray, B. B.; Jayamma, Y.; Chatterjee, M. *J. Org. Chem.* **1995**, *60*, 5958.
21. Damour, D.; Depezay, J. C.; Le Merrer, Y.; Mignani, S.; Pantel, G.; Poitout, L. French Patent application 95 05510.
22. For precedent neighbouring nitrogen participation, in piperidine, see: Hammer, C. F.; Heller, S. R.; Craig, J. H. *Tetrahedron* **1972**, *28*, 239, and ref cited therein; and in azepane, see: (a) Johnson, P. Y.; Lisak, J. *Tetrahedron Lett.* **1975**, 3801. (b) Sakanov, S.; Haruswa, S.; Yamazaki, N.; Yoneda, R.; Kurhara, T. *Chem. Pharm. Bull.* **1990**, *38*, 2981.
23. (a) Cossy, J.; Dumas, C.; Michel, P.; Pardo, D. G. *Tetrahedron Lett.* **1995**, *36*, 549. (b) Harding, K. E.; Burks, S. R. *J. Org. Chem.* **1984**, *49*, 40. (c) Setoi, H.; Takeno, H.; Hashimoto, M. *Heterocycles* **1986**, *24*, 1261. (d) Furneaux, R. H.; Gainsford, G. J.; Mason, J. M.; Tyler, P. C. *Tetrahedron* **1994**, *50*, 2131. (e) Furneaux, R. H.; Mason, J. M.; Tyler, P. C. *Tetrahedron Lett.* **1995**, *36*, 3055.
24. For precedent syntheses, see: Zou, W.; Szarek, W. *Carbohydr. Res.* **1993**, *242*, 311, and references cited therein.
25. For precedent syntheses of DMDP, see: (a) Fleet, G. W. J.; Smith, P. W. *Tetrahedron* **1987**, *5*, 971. (b) Chorgharde, M. S.; Cseke, C. T. *Heterocycles* **1995**, *40*, 213, and references cited therein.
26. Bernotas, R. C.; Cube, R. V. *Synth Commun.* **1990**, *20*, 1209, and refs cited therein.
27. For precedent syntheses of DMJ, see: (a) Park, K. H.; Yoon, Y. J.; Lee, S. G. *J. Chem. Soc. Perkin Trans. 1* **1994**, 2621. (b) Zou, W.; Szarek, W. A. *Carbohydr. Res.* **1994**, *254*, 25. (c) Baxter, E. W.; Reitz, A. B. *J. Org. Chem.* **1994**, *59*, 3175, and refs cited therein. (d) Legler, G.; Jülich, E. *Carbohydr. Res.* **1984**, *128*, 61.
28. Wolf, H. *Org. React.* **1974**, *3*, 327.
29. For precedent syntheses, see: (a) Kinast, G.; Schueller, A. M.; Schroeder, T. *Bayer Pat.* **1986**, DE 86-3220645. (b) Khanna, I. K.; Mueller, R. A.; Weier, R. M.; Stealey, M. A. Searle & Co. Patent 1992, US-92-861686, US-92-861696.
30. Brown, H. C.; Garg, C. P.; Liu, K. T. *J. Org. Chem.* **1971**, *36*, 387.
31. For precedent syntheses, see: (a) Bernotas, R. C.; Ganem, B. *Tetrahedron Lett.* **1985**, *26*, 4981. (b) Fleet, G. W. J.; Fellowx, L. E.; Smith, P. W. *Tetrahedron* **1987**, *43*, 979. (c) Bashyal, B. P.; Chow, H. F.; Fellows, L. E.; Fleet, G. W. J. *Tetrahedron* **1987**, *43*, 412. (d) Bashyal, B. P.; Chow, H. F.; Fleet, G. W. J. *Tetrahedron Lett.* **1986**, *31*, 3205. (e) Manning, K. S.; Lynn, D. G.; Shabanowitz, J.; Fellows, L. E.; Shing, M.; Schrire, B. D. *J. Chem., Chem. Commun.* **1985**, 127.
32. Furthermore, **20f**, or its L-ido isomer, reacts with 1.4 equivalents of mesyl chloride in NEt₃ at 0 °C to give directly the corresponding chloromethyl-piperidine in 60% yield. See ref 21.
33. Due to the unsatisfactory correlation of the physical data of **31** with: Kilonda, A.; Dequeker, E.; Compennolle, F.; Delbeke, P.; Toppet, S.; Babady-Bila; Hoornaert, G. J. *Tetrahedron* **1995**, *51*, 849, **31a** has been partly hydrogenolyzed to **31b**.
34. (a) Cope, A. C.; Baxter, W. N. *J. Am. Chem. Soc.* **1955**, *77*, 393. (b) Miller, A. D. U.S. 3,856,783, 1974. *Chem. Abstr.* **1975**, *82*, 98010u. (c) Miller, A. D. U.S. 3,953,596, 1976. *Chem. Abstr.* **1977**, *7*, 135351g. (d) Hiltemann, R.; Wallweber, H.; Hoffmeister, F. H.; Kroneberg, H. G. Ger. 1,795,848, 1977. *Chem. Abstr.* **1978**, *88*, 105183g.
35. Lundblad, G.; Bjare, U.; Lybing, S.; Malhen, A. *Int. J. Biochem.* **1983**, *6*, 835.
36. Di Bello, I.; Dorling, P.; Fellows, L. E.; Winchester, B. *FEBS Letter* **1984**, *176*, 61.

(Received in U.S.A. 15 August 1996; accepted 25 October 1996)